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Artemisinin, a natural product and its derivatives are potent antimalarial 
compounds, which have shown anticancer activity. In this study, we further 
characterized a novel artemisinin derivative namely EXP57EA which was 
previously designed and synthesized by the Chemistry Department at the 
University Of Cape Town. We determined the effect of EXP57EA on a panel 
of cancer cell lines, characterized the mode of cell death and also performed 
preliminary investigations of the signaling pathways that trigger the mode of 
cell death.  
 
Dihydroartemisinin (DHA), EXP57EA and cisplatin were screened on a 
selected panel of cancer cell lines: 3 esophageal cancer cell lines WHCO1, 
WHCO5, KYSE150; one breast cancer cell line MDA-MB-231 and one 
cervical cancer cell line SiHa. The 3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide (MTT) assay, and analysis with GraphPad prism 
software were used to calculate IC50 values.  EXP57EA displayed toxicity in 
the panel of cancer cell lines studied, and had lower IC50 values (IC50 values 
were ranging from 15.8 µM to 25.1 µM) than DHA and cisplatin. DHA was 
only active in two cells lines: WHCO1 (21.3 µM) and WHCO5 (77.3 µM), IC50 
values of cisplatin were ranging from 31.2 µM to 108.1 µM.   EXP57EA was 
further investigated to understand the mode of cell death activated in the 
panel of cancer cell lines.     
 
The results showed that EXP57EA did not induce apoptosis in any of the cell 
lines studied, whereas DHA induced apoptosis, based on the PARP 
cleavage assay. In contrast, treatment with EXP57EA induced the 
appearance of vacuoles in treated cells compared to untreated cells, which 
was suggestive of autophagy. Autophagy was monitored by analyzing the 
expression level of two autophagy markers, Beclin1 and LC3-II by western 
blot. It was observed that EXP57EA treatment caused changes in the 
expression levels of both Beclin1 and LC3-II.   We showed that EXP57EA 
induced elevated levels of autophagy, based on an increase in the flux of 
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autophagy in the treated cells, since the lysosomal inhibitors ammonium 
chloride (NH4Cl) and chloroquine substantially blocked LC3-II turnover in 
WHCO1 (confirmed previous result in our laboratory) and SiHa cancer cell 
lines.    
  
Furthermore, we also showed that treatment with EXP57EA resulted in 
increased expression of CHOP (by Real-Time PCR), and activated the 
PERK/eIF2α pathway, since treatment of WHCO1 cells with EXP57EA 
stimulated phosphorylation of eIF2α, suggesting that ER stress might be 
involved in mediating EXP57EA-induced cell death. Our results also 
suggested that EXP57EA activated the JNK pathway since treatment of 
WHCO1 and WHCO5 cells with EXP57EA stimulated phosphorylation of c-
jun and resulted in elevated levels of total c-jun. These results suggested the 
JNK pathway might also be involved in EXP57EA-induced cell death.  
However, the proposed involvement of the PERK/eIF2α pathway and the 
JNK pathway in EXP57EA-mediated autophagy is of a preliminary nature, 
and further work will have to be done to confirm the involvement of these 
pathways.  
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CHAPTER 1:  
  
  
 LITERATURE REVIEW  
	  	  
	  
 1.1    Cancer: A global health problem 
     
Non-communicable diseases (NCDs) constitute a major health crisis 
worldwide illustrated by the high prevalence of diseases such as 
cardiovascular disease, cancer, stroke and diabetes (Beaglehole et al. 2011). 
It was reported that the incidence of cancer surpassed AIDS/HIV, 
tuberculosis and malaria (Moten et al. 2014). Based on estimates, there were 
12.4 million estimated new cancer cases and 7.6 million cancer-related 
deaths in low and middle-income countries in 2008 (Ferlay et al., 2012). In 
2012, approximately 14 million new cancer cases were reported, and this 
figure is anticipated to increase over the next twenty years (WHO, 2014). 
With the number of cancer-related deaths predicted to increase substantially 
due to the adoption of a lifestyle that is prone to cancer, namely physical 
inactivity, excess smoking and unhealthy diet (Parkin et al. 2002; 
McCormack & Schüz 2012), it is necessary to increase our effort to fight this 
disease. This project will focus on exploring natural product derivatives as a 
source of compounds that may have activity against cancer cells, and could 
be developed into chemotherapeutic agents. There are a number of options 
open to address the burden of cancer that confronts us: (1) prevention by 
reducing the exposure of individuals to risk factors associated with cancer 
such as tobacco, physical inactivity, infection with viruses such as hepatitis B 
or C, overweight and obesity, alcohol consumption, ionizing radiation from 
natural, industrial and medical sources (Parkin et al. 2002); (Darby et al. 
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2005) (2) it is well known that diagnosing cancers at an early stage of the 
disease provides patients with the best possible chance of survival (Berry et 
al. 2005; Siegel et al. 2015) (3) medical treatment varies from surgical 
excision, chemotherapy and radiotherapy. The exact treatment regime and 
combination thereof depend on the type of cancer and stage of the disease 
(Siegel et al. 2015; Freedman et al. 2012; Machiels et al. 2014).  
1.2     Natural products as a source of novel chemotherapeutic drug 
leads    
 
The use of plants as medicinal treatments started thousands years ago and 
the first records come from Mesopotamia. Those reports record the 
widespread use of up to 1000 plants extracts for the treatment of various 
ailments (Tobin et al. 2012).  
 
Natural products and compounds isolated from plants have been considered 
as prototypes or leads in drug development and their molecular modifications 
have resulted in compounds with remarkable therapeutic possibilities 
(Gordaliza 2007). Furthermore, natural products have served an important 
source for anticancer drug development, with approximately 55 % of small-
molecule anticancer agents derived from plants and other types of 
organisms, including terrestrial microbes and marine organisms (Newman & 
Cragg 2016).  As described below, plant-derived natural products and their 
derivatives have yielded a number of well-known chemotherapeutic agents 
still in use today.    
 
In 1880, the isolation of podophyllotoxin from podophyllum peltatum 
(Rosenthal & Meshnickb 1996) was reported. However, it was only in 1950 
that the correct structure of this compound was published (Nirmala et al. 
2011). Many podophyllotoxin ligands were isolated and introduced into 
clinical trials but failed due to efficacy and toxicity limitations (Prakash et al. 
2013). However, through extensive research, two active agents (derived from 
an analog 4’-dimethylepipodophyllotoxin) namely teniposide and etoposide 
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were developed and are currently clinically used in the treatment of various 
cancers including lymphomas, bronchial, small-lung, leukeamia and testicular 
cancers (Takahashi et al. 2005). Podophyllotoxin prevents the polymerization 
of tubulin into microtubules whereas the analog inhibits topoisomerase II, 
thus preventing the cleavage and resealing of DNA strands (Newman et al. 
2000).    
 
The Vinca alkaloids Vinblastine and Vincristine were isolated from the 
Madagascan herb Catharantus roseus. A crude extract of this plant was 
investigated in the laboratory for it antidiabetic potential using experimental 
animals, and the antileukemic activity of that crude extract was discovered by 
serendipity (Newman et al. 2000). Vinblastine is active against testicular, 
lymphoma, breast, head and neck, cervico-uterine and bladder cancers, 
whereas, Vincristine was found to be active against pediatric tumors, 
Hodgkin’s disease and also non-Hodgkin lymphoma. These drugs, like 
podophyllotoxin inhibit mitosis by binding to tubulin to prevent their 
polymerization into microtubules (Bhanot. et al. 2011).     
  
The successful use of podophyllotoxin and the discovery of the Vinca 
alkaloids highlighted the value of plants as potential sources of drug leads for 
cancer therapy, and triggered a wave of exploration and research into natural 
products. As part of this process, the Pacific Yew tree was one of many 
plants investigated and Paclitaxel (Taxol) was discovered (Cragg et al. 
1993).  The US FDA approved Taxol in 1992 for the treatment of metastatic 
ovarian cancer, with promising clinical trials observed for the treatment of 
breast, lung and head and neck cancers (Yue-Zhong Shu 1998). Docetaxel, 
a semisynthetic analog of paclitaxel, was found to be more potent due to 
better water solubility. This compound can be used in cancer patients 
resistant to paclitaxel and is active against locally metastatic breast and non-
small lung cancers (Fang & Liang 2005; Ojima et al. 2000). Paclitaxel and 
docetaxel also inhibit mitosis, however, they act as microtubule stabilizers, 
thus promoting their polymerization (Hait et al. 2007). 
  
Camptothecin, isolated from Camptotheca acuminate (Cragg & Newman 
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2005) was subjected to clinical trials by the National Cancer Institute (NCI) in 
1970 and withdrawn due to problems with water solubility and toxicity. To 
overcome these major drawbacks, the derivatives Irinotecan and Topotecan 
were developed and are used as second line treatment in various cancers 
(Fuchs et al. 2006).  Topotecan is effective against ovarian and small cell 
lung cancers and Irinotecan is effective against colorectal cancer (Liu et al. 
2006).  Exatecan is a synthetic derivative of camptothecin. This compound 
has been shown to be more efficient against tumours with better solubility 
and less toxicity compared to the parental compound, camptothecin 
(Reichardt et al. 2007). Exatecan was shown to be active against various 
tumors in vitro and in vivo. Camptothecin derivatives function to inhibit 
Topoisomerase I, interfering with DNA replication and transcription 
(Srivastava et al. 2005).  
 
In summary, natural products derived from plants currently play an important 
role in the development of drugs for the treatment of cancer. While the 
parental compounds isolated from plants may not be used directly as 
anticancer drugs, they can be used as leads for the development of novel 
compounds with substantially improved characteristics such as solubility and 
general toxicity. Among the promising compounds with activity against 
cancer is the natural-product derived antimalarial drug, artemisinin (Maria P. 
Crespo-Ortiz & Wei 2012).     
  
1.2.1    Artemisinin and its derivatives    
 
Quinghao is a Chinese medicinal herb commonly known as Artemisia annua 
or sweet wormwood (Maude et al. 2010). The use of this plant in the 
treatment of malaria was first reported around the second century. It was 
recommended to drink a mixture containing boiled quinghao for the treatment 
of fevers with sweating and jaundice. In 1967, the Chinese government 
initiated an extensive investigation into the antimalarial properties of 
quinghao, and reported the effectiveness of a crude extract in mice infected 
with plasmodium berghei (Hsu 2006). Other studies reported no toxicity when 
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rats, cats and dogs were given a high dose of this extract. In 1972, a 
colourless, needle-shaped crystal active ingredient of quinghao was isolated 
and three years later quinghaosu was chosen as the name of the new 
compound.  The western name for quinghaosu was artemisinine, which 
changed to artemisinin a few years later (Maude et al. 2010). 
  
Artemisinin is a terpene lactone, which consists of a 1, 2, 4-trioxane, ring 
structure and contains an endoperoxide bridge (C-O-O-C). Despite its 
success as an antimalarial drug, this compound shows some 
pharmacological limitations such as poor bioavailability, its solubility in water 
and oil is low, and finally the half-life of this compound is short, approximately 
2.5 hours in vivo (Ashton et al. 1998).  The development of semisynthetic 
and fully synthetic artemisinin-like endoperoxide compounds was attempted 
to alleviate these limitations (Das 2015). The first generation of semisynthetic 
artemisinin-like compounds includes the lipid soluble arteether and 
artemether and the water-soluble artesunate, which are frequently used in 
the treatment of different malarial parasites including the resistant forms 
(Haynes et al. 2002). The second generation of artemisinin-like compound 
includes artemisone with substantially improved characteristics such as a 
long half-life and low toxicity (Das 2015). All semisynthetic artemisinin are 
obtained from dihydroartemisinin (DHA), which has been reported to be the 
most potent active metabolite of artemisinin (Du et al. 2013). The fully 
synthetic artemisinin-like compounds such as trioxolanes and ozonides are 
synthesized retaining the endoperoxide bridge, which is essential for their 
activation and efficacy as an anti-malarial agent (Creek et al. 2008; Jefford 
2007).  
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Figure 1.1: Structures of artemisinin and its first-generation (Dihydroartemisinin and 
Artesunate) and second-generation (Artemether, Arteether and Artelinic acid) 
derivatives (Firestone & Sundar 2009).   
 
1.2.2    Artemisinin derivatives as potential chemotherapeutic agents  
 
Numerous studies have investigated the anticancer effect of artemisinin and 
its semisynthetic derivatives in vivo and in vitro (Efferth et al. 2003).  It has 
been reported that the proposed mechanism of action of Artemisinin is the 
iron-mediated cleavage of the endoperoxide bridge generating ROS and 
carbon-centered radical molecules that causes extensive protein damage 
and ultimately death of the malaria parasites, and presumably, cancer cells 
too (Maria P. Crespo-Ortiz & Wei 2012).     
 
Woerdenbag and colleagues reported the first study on the cytotoxicity of 
artemisinins and its derivatives in 1993. In this study, artemisinin displayed 
activity in the micromolar range (29.8 µM) against Ehrlich ascites tumour 
(EAT) cells. However these cells were more susceptible to artemether, 
arteether, artesunate, artelinic acid and sodium artelinate with IC50 values 
between 12.2 µM and 19.9 µM (O’Neill et al. 2010; Woerdenbag et al., 1993). 
Further studies were conducted on the cytoxicity of these compounds on 
their antimalarial activity, and likely some of their
anticancer activities, is an endoperoxide bridge,
which is cleaved in the presence of iron leading
to generation of free-radical reactive oxygen
species (ROS) (Ref. 5). In addition to its well-
established antimalarial properties, compelling
evidence has emerged in the field showin that
artemisinin-related compounds have potent
anticancer activities in a variety of human
cancer cell types.
Overview of anticancer properties
of artemisinin
Molecular, cellular and physiological studies
have demonstrated that, depending on the
tissue type and experimental system,
artemisinin and its derivatives arrest the
growth, induce an apoptotic response, alter
hormone responsive properties and/or inhibit
angiogenesis of human cancer cells
(summarised in Table 1). The Developmental
Therapeutics Program of the National Cancer
Institute (NCI), USA, which analysed 55 human
cancer cell lines, showed that artesunate, the
semisynthetic derivative of artemisinin, has
strong anticancer activity against leukaemia and
colon cancer cell lines, and has intermediate
effects on melanomas, breast, ovarian, prostate,
central nervous system, and renal cancer cell
lines (Ref. 6). Moreover, the highly stable
artemisinin-derived trioxane dimers were
shown to inhibit the growth of and selectively
kill several human cancer cell lines without
inducing cytotoxic effects on normal
neighbouring cells (Ref. 7). One proposed
mechanism by which artemisinin targets cancer
cells is cleavage of the endoperoxide bridge by
the relatively high concentrations of iron in
cancer cells, resulting in free radicals such as
ROS and subsequent oxidative damage as well
as iron depletion in the cells (Ref. 8). This
mechanism resembles the action of artemisinin
in malarial parasites. In addition to possessing
higher iron influx via transferrin receptors,
cancer cells are also sensitive to oxygen radicals
because of a relative deficiency in antioxidant
Chemical structures of artemisinin and its bioactive derivatives









R1 = H, R2 = OH
R1 = H, R2 = OMe
R1 = H, R2 = OEt
R1 = H, R2 = OCH2C6H5CO2H














Figure 1. Chemical structures of artemisinin and its bioactive derivatives. The chemical structures of
artemisinin and derivatives show the endoperoxide bridge which is the reactive moiety for the ferrous ion,
leading to generation of reactive oxygen species and eventual killing of the malarial parasite. These
derivatives differ in their relative stability owing to differences in chemical structure, and have been shown to
display different potency as anticancer agents.
expert reviews
http://www.expertreviews.org/ in molecular medicine
2
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HeLa S3 and Ehrlich ascites (EN19) cell lines and it was reported that 
artemisinin and its derivatives inhibited the growth of these tumour cells 
based on the results of the clonogenic assay (Beekman et al. 1996). 
A study conducted by Efferth et al (2003) aiming at determining the effect of 
artesunate in 55 human cancer cell lines concluded that artesunate inhibits 
proliferation of leukemia, colon, melanoma, breast, prostate and Central 
Nervous System (CNS) cancer cell lines (Efferth et al. 2003). It has also 
been reported that DHA exerted its anticancer effects against pancreatic, 
lung and leukemic cancer cell lines (Lu et al. 2009). Furthermore, artemisone 
was showed to be more potent than artemisinin and able to successfully 
interact with other anticancer agents (Gravett et al. 2011).    
 
Artemisinin has been shown to be effective against cancer by causing DNA 
damage or by interfering with different molecular signaling pathways involved 
in the disease of cancer. Du et al., 2010 demonstrated that the artemisinin 
derivative, artesunate induced DNA damage and membrane disruption in a 
pancreatic cancer xenograft mouse model in vivo (Du et al. 2010).   
 
Artemisinin-like semisynthetic compounds are able to inhibit cancer cell 
growth by inhibiting signaling pathways involved in proliferation and by 
disrupting cell cycle checkpoints (Efferth et al. 2003; Das 2015). The most 
potent artemisinin-like compound, DHA showed arrest at G2/M phase in 
pancreatic, osteosarcoma, leukemia and ovarian cancer cell line lines, while 
artesunate treatment interfered with G2 in osteosarcoma, ovarian and A431 
human epidermoid carcinoma cells (Gravett et al. 2011; Jiao et al. 2007). 
The growth arrest was associated with altered expression and activity of 
CDK2-4 and CDK2-6 responsible for the transition of G1 to S phase 
(Firestone & Sundar 2009; Johnson & Walker 1999).   
 
The anticancer activity of artemisinin-derivatives has also been linked to the 
induction of apoptosis in cancer. Apoptosis is an extensively and well-
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described process that is controlled by the Bcl2 genes family. The Bcl2 
genes family includes the antiapoptotic bcl-2 genes and the proapoptotic 
genes Bax; Bad, Bim; Bik, Noxa and Puma that play a regulatory role in 
cancer through the mitochondria. Cell death through the intrinsic apoptosis 
pathway is achieved by an increase in the Bax/Bcl2 ratio, which results in 
release of mitochondrial cytochrome c and causes the activation of 
Caspases. It has been shown that artemisinin derivatives commonly induced 
rapid cell death via apoptosis through the disruption of the mitochondrial 
organelle, which then activates downstream events leading to cell death.  
Singh and Lai, (2004) reported that treatment of Leukemia cancer cells with 
DHA resulted in apoptosis after 1 hour (Singh & Lai 2004). DHA and 
artesunate treatments were shown to induce overexpression of the 
proapoptotic Bax, increased ratio of Bax/Bcl2, the release of cytochrome c 
and activation of caspases 9 and 3 resulting in osteosarcoma cell death.  
Activation of Caspase 8 and reduction in the expression of cyclin B1 and NF-
KappaB was also observed. The extrinsic apoptotic pathway is mediated by 
the extracellular death ligands binding to various death receptors including 
death receptor 5 (DR5) to eliminate unwanted cells during development. A 
study done by He et al., 2010 reported that DHA treatment increased the 
expression of death receptor 5, which consequently resulted in apoptosis in 
different prostate cancer cell lines. Moreover, co-treatment with TRAIL 
enhanced the apoptotic effect of DHA by up to 35 % in the same cell line (He 
et al. 2010).      
 
The role of the endoperoxide bridge of artemisinin and its derivatives has 
been extensively studied and reported to be pharmacologically important for 
their antimalarial effects (Das 2015). In the malarial parasite the activation of 
this bond is mediated through high concentrations of Ferrous iron, which 
consequently leads to the generation of free radicals (Bustos et al. 1994; 
Olliaro et al. 2001; Rosenthal & Meshnickb 1996). Interestingly, some cancer 
researchers have found that the anticancer effect of artemisinin and its 
derivatives has been also associated with the endoperoxide bridge (Mercer 
et al. 2007; Meunier et al. 2010). It was found that artemisinin compounds 
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without the endoperoxide bridge did not completely inhibit their anticancer 
effect. However, toxicity to cells was reduced compared to the compounds 
containing the trioxane ring structure (Maria P. Crespo-Ortiz & Wei 2012).  
 
Iron ferrous and heme are important in the activation of artemisinin and its 
derivatives (Hamacher-Brady et al. 2011; Zhang & Gerhard 2009). It has 
been shown that the toxicity of these compounds was triggered by high influx 
of iron or iron-saturated holotransferrin, which then resulted in an increase of 
their anticancer activity up to 100 fold (Lai & Singh 1995; Lu et al. 2010; Lu et 
al. 2011; Mercer et al. 2011). Moreover, Lai et al. 2009 showed that 
conjugated artemisinin with an iron-carrying compound exhibited higher 
anticancer activity than artemisinin alone (Lai et al. 2009).  
 
Anticancer drugs have certain properties such as high oxidative stress 
(ROS). Reactive oxygen species damage often occurs due to increased 
metabolic activity and the reduced expression levels of antioxidants in 
malignant cells (Pieniążek et al. 2013). Crespo-Ortiz et al. 2001 have 
suggested a possible scheme to explain the anti-cancer effects of 
artemisinins relating treatment of artemisinins to the generation of ROS and 
eventually activation of apoptosis (figure 1) (Bostwick et al. 2000; Mercer et 
al. 2007).  Du et al. 2010 reported that microscopic analysis of cancer cells 
treated with artemisinin derivative namely artesunate showed early apoptotic 
subcellular changes by the activation of ROS (Du et al. 2010). Another study 
demonstrated that the generation of ROS preceded the toxicity of artesunate 
in the cervical Hela cancer cell line suggesting that ROS was the triggering 
factor (Zhou et al. 2012).     
 
Factors such as calcium metabolism, endoplasmic reticulum stress (ER) and 
the binding calcium protein TCTP (translationally controlled tumour protein) 
can also regulate the anticancer effects of artemisinin (Noori & Hassan 2011; 
Stockwin et al. 2009). It has been found that the common IC50 value of 
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artesunate in a panel of cancer cell lines from the national cancer institute 
(NCI) correlated inversely with the microarray mRNA expression level of 
TCTP.  Cancer cells expressing high levels of TCTP were found to be more 
sensitive to artesunate compared to those expressing low levels of TCTP.  
Even though the functional role of TCTP in the anticancer activity of 
artemisinin still needs to be investigated, the above-mentioned results 
suggest such a role (Baudet et al. 1998; Bommer & Thiele 2004).  
 
Given that this project will explore cell death mechanisms activated by 
artemisinin and its derivatives, below, we discuss some of the different 
programmed cell death pathways that can be involved in cell death.     
1.3    Programmed Cell death in cancer   
  
One of the major processes controlling cell fate is programmed cell death.  It 
is a genetically regulated process involved in development, homeostasis and 
removal of unwanted cells (Levine 2007; Hanahan & Weinberg 2011) and 
which has recently generated much interest because these processes 
typically represent the end-point of cancer treatment (Bialik et al. 2010; Tan 
et al. 2009).  Three types of programmed cell death (PCD) are generally 
recognized: apoptosis (or PCD I), autophagy (or PCD II) and Necrosis (or 
PCD III). 
 
Apoptosis or PCD I is the best characterized and reported cell death 
mechanism. PCD I plays an important role in quality control and repair 
processes by eliminating damaged, unwanted cells, which are critical for the 
development of various organisms (Hengartner 2000).   
 
PCD II or autophagy is a catabolic process in eukaryotic cells involved in the 
removal of organelles and long-lived proteins. Moreover, autophagy plays a 
role in the quality control of organelles and proteins to enhance cell survival 
under starvation conditions (Klionsky 2005).  
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In contrast to apoptosis and autophagy which are energy dependent, 
involved in quality control and affect individual cells or clusters of cells, 
programmed necrosis has been reported to be a passive process affecting 
only large fields of cells.  Interestingly, necrosis is not initiated due to the 
activation of one signaling pathway, but as a result of a crosstalk between 
several signaling pathways (Sun & Peng 2009).       
 
Even though the three PCD assist in the maintenance of tissue regulation 
and homeostasis, dysregulation of PCD could lead to various diseases, 
including cancer. It has been reported that the type of PCD activated 
depends on the nature of the stimulus, time of exposure to the stimulus and 
the cell environment, because of the extensive cross-talk between the 
different cell death pathways. Moreover, during cancer development, 
deficient cell death and tumor resistance to chemotherapy or radiation 
therapy often occurs; strongly suggesting that PCD might be involved in 
anticancer therapy.  Therefore, targeting PCD pathways may enhance 
anticancer therapies (Mashima & Tsuruo 2005).    
 
The various programmed cell death pathways namely apoptosis, autophagy 
and necrosis can be distinguished by their phenotypic characteristics, which 
affect various organelles, membranes as well as the nucleus of cells (Boujrad 
et al. 2007). The morphology of cells undergoing apoptosis includes nuclear 
fragmentation, cell shrinkage, blebbing and membrane bound bodies 
(Nishida et al. 2008). Autophagy involves the formation of the 
autophagosome leading to double-membrane bound vesicle structures 
surrounding the cytoplasmic contents. The double-membrane vesicle fuses 
with the lysosome resulting in the degradation of the cytoplasmic contents 
(Chen et al. 2010; Li et al. 2011; Liu et al. 2011). Cell swelling, appearance of 
empty space in the cytoplasm, disruption of plasma membrane and 
preservation of the nucleus is associated with programmed necrosis (McCall 
2010; Wu et al. 2012). Considering the information presented later in this 
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report, PCD I (apoptosis) and PCD II (autophagy) will be discussed in more 
detail.    
 
1.3.1    Apoptosis   
 
Tremendous advances regarding the genetics and biology of cancer has 
gained interest, and one of the best achievements is the characterization of 
PCD I. It is extensively reported that mutations of certain oncogenic genes 
resulting in apoptosis suppression lead to tumor initiation, progression and 
metastasis (Liu et al. 2011). Thus, more effective research needs to be done 
in order to uncover the various molecular mechanisms underlying apoptosis 
in the hope of improving anticancer therapies.    
 
Kerr et al first described apoptosis in 1972, and since then it has received 
great attention (Ouyang et al. 2012). Apoptosis plays an important role in 
maintaining cell populations and acts to protect against toxic compounds. It 
can be triggered by intracellular signals in response to cellular stress such 
as: oxidative damage caused by reactive oxygen species (ROS), 
chemotherapeutic drugs, increased calcium concentration and hypoxia 
(Annunziato et al. 2003; Shimizu et al. 1996). Extracellular signals can also 
trigger apoptosis by bacterial pathogens, nitric oxide, toxins, hormones as 




The intrinsic or mitochondrial apoptotic pathway is triggered when cells 
sense intracellular signals such as DNA damage or nuclear instability. These 
stimuli then activate pro and anti- apoptotic family members consequently 
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The Bcl-2 family members include the anti-apoptotic family (Bcl-2, Bcl-xL, 
Bcl-w and Mcl-1), which are involved in protecting cells from cytotoxic 
agents. The pro-apoptotic family includes promoters containing various BH 
domains and BH3-only members with a single BH domain. The promoters 
Bax, Bak and Bok are often found on the outer membrane of the 
mitochondria and regulate apoptosis in a positive manner. The BH3-only 
members are divided into sensitizers and direct activators. The sensitizer 
members Bad, Noxa, Bik, Hrk, and PUMA bind and inhibit anti-apoptotic Bcl-
2 members whereas the activators Bid and Bim interact with Bax, Bak and 
Bok. Moreover, Bid and Bim can stimulate Bax and Bak homodimerization 
leading to the disruption of the outer mitochondrial membrane (figure 1.2).   
 
The mitochondrial outer membrane permeabilization (MOMP) induces 
cytochrome c release into the cytosol. Cytochrome c recruits Apaf-1 
(Apoptotic protease activating factor 1) and pro-caspase 9 in the presence of 
ATP. Cytochrome c, Apaf-1 and procaspase 9 then form a complex called 
the apoptosome. Both pro-caspase and caspase 9 contains the protein 
interaction domain CARD (caspase activation and recruitment domain). This 
domain facilitates the binding and activation of pro-caspase and caspase 9 
with Apaf-1. Once activated, caspase 9 then activates and cleaves pro-
caspase 3 to its active form caspase 3, which is an executioner of apoptosis.   
   
Other important proteins such as Smac/Diablo (second mitochondria-derived 
activator of caspases/Direct IAP-binding proteins with low pI), HtrA2/Omi 
(High temperature requirement/Omi stress regulated endoprotease) and AIF 
(Apoptosis inducing factor) are also released from the mitochondria. 
Smac/Diablo and HtrA2 proteins act by blocking the IAP (Inhibitor of 
apoptosis protein) family, which comprise eight endogenous caspase 
inhibitors that prevent apoptosis from occurring (Fulda & Debatin 2013). The 
IAP family includes various proteins such as XIAP (X-linked inhibitor of 
apoptosis), cell IAP1 (cIPA1) and cell IAP2 (cIAP2), survivin, neuronal 
apoptosis inhibitory protein (NAIP), Bruce (Apollon) and ILP-2. Among this 
family, XIAP has been reported to be the strongest anti-apoptotic protein. It 
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blocks apoptosis by inhibiting caspase 9 activation and by binding to 








Figure 1.2:  The apoptotic pathways. The binding of FasL, TNFα and TRAIL to 
Fas, TNFR1 and TRAIL R1/R2 activates the extrinsic pathway and this allows the 
recruitment of FADD or TRADD. The latter recruits caspase 8 and activates 
caspase 3. Pro-apoptotic Bcl-2 and Bcl-xL and anti-apoptotic Bax and Bak mediate 
the intrinsic pathway. Stimuli such as DNA damage, hypoxia and ER stress cause 
PUMA and Bim to inhibit Bcl-2 and Bcl-xL. This allows permeabilization of the outer 
mitochondrial membrane by Bax/Bak, which consequently results in the release of 
cytochrome c. Released cytochrome c in turn activates, both caspases 9 and 3 
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Extrinsic pathway 
   
The extrinsic or death receptors (DR) pathways play an important role in 
apoptosis. DRs belong to the tumor necrosis factor (TNF) receptor family, 
which comprises various proteins.  These proteins function by regulating cell 
death and survival as well as differentiation and immune system regulation 
(Debatin & Krammer 2004). To date, eight members have been reported and 
these include tumor necrosis factor receptor 1 (TNFR1), Fas (fatty acid 
synthetase) or CD95, DR3, TNF-related apoptosis-inducing ligand receptor 1 
(TRAILR1), TRAILR2, DR6, ectodysplasin A receptor  (EDAR) and nerve 
growth factor receptor (French & Tschopp 2003).  
  
The extrinsic pathway relies on the Fas death receptor which is activated by 
Fas-L (Fas ligand) / Fas model (Zapata et al. 2001). Upon ligand binding, 
Fas-L combines with Fas resulting in a Fas-Fas-L death complex. This 
complex then interacts with FADD (death domain-containing protein) and 
procaspase 8 (initiator caspase) forming a death inducible signaling complex 
or DISC (Lavrik et al. 2005).  The activation of DISC results in caspase 8 
cleavage, which in turn activates procaspase 3 and Bid. The truncated Bid 
translocates into the mitochondria to activate Bax/Bak, causing the 
permeabilization of the mitochondrial outer membrane and release of 
cytochrome c, which in turn activates caspase 3 (Liu et al. 2011) (figure 1.2). 
 
      
1.3.2    Autophagy  
  
1.3.2.1 Function of autophagy in cancer cells  
  
Autophagy, a term referring to ‘’ eat oneself ‘’ (auto (self) and phagy (to eat)) 
is activated by various stimuli including radiation, treatment with various 
chemical compounds (Bufalin, Ursolic acid), nutrient starvation, accumulation 
of misfolded proteins in the endoplasmic reticulum, hypoxia and oxidative 
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stress (Chen et al. 2010; Yang & Klionsky 2010; Shen, Zhang, Wang, et al. 
2014b).    
  
Typically, macroautophagy, microautophagy and chaperone-mediated 
autophagy (CMA) are the three forms of autophagy that have been 
recognized so far (Mizushima & Komatsu 2011). Macroautophagy or 
autophagy plays a role in the fusion of the complete autophagosome 
structure with the lysosome. Microautophagy, however, is poorly described 
but is thought to be a non-selective form of degradation involving the 
engulfment of the cytoplasm by the lysosomal membranes. CMA involves 
targeting and transferring cytosolic proteins into the lysosome for degradation 
(Das 2015). Targeted proteins must have a specific amino acid sequence 
that is recognized by HSPA8/HSC70. Once recognized, the cargo is then 
directed for degradation (Gottlieb et al. 2015). 
  
Autophagy is a catabolic process involved in normal development, 
senescence, invasion, defense and in various pathological conditions 
including cancer (Klionsky & Emr 2000; Levine & Klionsky 2004; Meijer & 
Codogno 2004).  One of the main functions of autophagy is to maintain cell 
survival during stress.  Autophagy also plays a role in protein and organelle 
quality control to avoid the accumulation of unfolded proteins (Komatsu et al. 
2005; Wang & Klionsky 2003). Autophagy was also reported to play a role in 
conditions of stress. For example, DNA damage caused by 
chemotherapeutic agents, hypoxia or irradiation therapy results in the 
activation of autophagy, which consequently leads to autophagy cell death 
(Chen & Karantza-Wadsworth 2009; Klionsky & Emr 2000; Mathew et al. 
2007; Papandreou et al. 2008).  
 
Autophagy was primarily considered a pro-survival mechanism, to allow cells 
to acquire sufficient nutrients under unfavorable conditions. However, there is 
evidence in the literature suggesting that autophagy can also result in cell 
death under certain conditions (Liu & Levine 2015). A study conducted by 
Shimizu et al, 2004, showed that by treating Bax/Bak double-knockout 
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mouse embryonic fibroblast with etoposide or staurospine, the mouse died in 
a non-apoptotic way with an increase in vacuoles observed (Shimizu et al. 
2004). In the same study, it was shown that the non-apoptotic death of 
mouse fibroblasts was suppressed by 3-methyl adenine (3-MA) an inhibitor 
of autophagy), concluding that this mechanism of cell death occurred through 
autophagy (Shimizu et al. 2004). In addition, Chen et al., 2008 demonstrated 
that hydrogen peroxide (H2O2) and 2-methoxyestradiol (2-ME) caused 
autophagic cell death in the transformed cell line HEK293 as well as Hela 
and U87 cell lines. Moreover, it was shown in this study that blocking the 
accumulation of autophagasome through 3-MA or knocking down autophagy 
genes Beclin1, ATG5 and ATG7, inhibits oxidative stress induced-cell death. 
Furthermore, blocking ROS generation also inhibited autophagy induced-cell 
death (Chen et al. 2008).  
 
Autophagy has developed as an area of interest over the past years as a 
result of the discovery of AuTophaGy-related (Atg) family genes. These 
genes were first investigated in yeast but their mammalian orthologues have 
been identified (Inguscio et al. 2012). For the sake of this study, mammalian 
orthologues will be discussed. Currently, 31 Atg proteins have been identified 
that participate in the molecular regulation of autophagy and most of them 
participate in the formation of the autophagosome structures, central to the 
autophagy process (Suzuki et al. 2007).    
 
1.3.2.2 The Autophagy pathway 
  
The autophagy process involves three main stages: initiation of the pre-
autophagosome, elongation of the autophagosome and maturation of the 
autophagosome.  The initiation of the pre-autophagosomal structure involve 
interactions between various proteins resulting in an enclosed double-
membrane structure (or autophagosome) that fuses with lysosomes forming 
autolysosomes responsible for degrading its content (He & Klionsky 2009).  
Four different complexes are involved in the initiation process: two kinase 
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complexes (mTOR C1 and ULK1/2) (figure 1.3) and two ubiquitin-like 
conjugation systems (Inguscio et al. 2012). 
   
The first kinase complex consists of the mammalian Target of Rapamycin 
(mTOR), which regulates the autophagy process (He & Klionsky 2009) 
(figure 1.3). Under nutrient-rich conditions, mTOR inhibits autophagy by 
phosphorylation of the ULK1/2 complex (unc-51-like kinase: mammalian 
homologs of Atg1). In nutrient-poor conditions, mTOR dissociates from the 
ULK1/2 complex, which dephosphorylates ULK1/2. This then causes 
dephosphorylation and activation of Atg13 and Atg17 (or focal adhesion 
kinase family-interacting protein of 200 kDa, FIP200).  The autophagy 
initiation is completed when the ULK1/2-ATG13-FIP200 complex 
accumulates at the site of the phagophore (He & Klionsky 2009; Ohsumi 











Figure 1.3: mTOR regulates the autophagy process in nutrient-rich and 
nutrient-poor conditions. In nutrient-rich conditions, active mTOR associates with 
and hyperphosphorylates ULK1/2, this in turn results in the hyperphosphorylation of 
Atg13 and therefore subsequently inhibiting autophagy. In nutrient-poor conditions, 
mTOR dissociates from ULK1/2, causing hypophosphorylation of ULK1/2 complex, 
Atg13 and phosphorylation of FIP200, thus activating autophagy (Zeng & Kinsella 
2011). 
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In mammalian cells, class I, II and III PI3K have been identified, with class I 
and III involved in the regulation of autophagy. Class I members cause the 
inhibition of autophagy. However, the class III, the hVPS34 (human Vesicular 
protein sorting 34) (figure 1.4) and its subunits including p150 (hVPS15 or 
phosphoinositol-3-kinase regulatory subunit 4), Beclin1 (Atg6 or Vps 30, a 
coiled-coil, myosin-like Bcl-2 interacting protein) and Atg14L are necessary 
for the induction of autophagy and initiation of the pre-autophagosome 




















Figure 1.4 Autophagy pathways:  During autophagy initiation, the class III PI3K 
including hVPS34-Beclin1 complex are necessary for recruiting Atg12-Atg5-Atg16L1 
and LC3-PE complexes.  These complexes function together to elongate the 
phagophore resulting in the complete autophagosome structure or mature 
autophagosome. The fusion of the autophagosome with the lysosome/endosome 
results in autolysosome. Autolysosome contains hydrolytic enzymes, which are 
responsible for degrading materials in the autophagosome (Karakaș & Gözüaçik 
2014). 
KARAKAŞ and GÖZÜAÇIK / Turk J Biol
722
2.2. Autophagosome expansion and closure
Two ubiquitylation-like systems are known to mediate 
autophagosome expansion: the Atg12-Atg5 conjugation 
system, and the microtubule-associated protein 1 light 
chain 3 (Atg8 in yeast and MAP1LC3 or shortly LC3 in 
mammals) lipidation system (Figure 1) (Kirisako et al., 
2000; Mizushima et al., 2001). In the first system, Atg12 
is activated by Atg7 (E1-like enzyme), then transferred 
to Atg10 (E2-like enzyme). Finally, Atg12 is covalently 
conjugated to the Atg5 protein (Mizushima et al., 2001). 
Subsequently, the Atg12-Atg5 conjugate interacts with 
Atg16 (ATG16L1 in mammals) to form a complex of 
higher molecular weight (Figure 1) (Fujita et al., 2008). In 
the yeast system, the Atg12-Atg5-Atg16 complex (ATG12-
ATG5-ATG16L1 complex in mammals) is mainly localized 
to the surface of autophagosomes, and it dissociates from 
membranes following autophagic vesicle completion 
(Mizushima et al., 2001; Itakura and Mizushima, 2010). 
In the second ystem, in order to xpose a glycine 
residue at its C terminal, LC3 protein is cleaved by ATG4B 
proteins soon after its synthesis. Processed protein stays in 
the cytosolic free form called LC3-I. Subsequently, LC3-I is 
activated by ATG7 (E1-like enzyme), transferred to ATG3 
(E2-like enzyme), and covalently linked to a lipid molecule, 
namely phosphatidylethanolamine (PE). The lipid-
conjugated LC3 form is called LC3-II and it is localized 
both on isolation membranes and autophagosomes (Satoo 
et al., 2009). Hence, demonstrations of LC3 lipidation 
and LC3-I to LC3-II conversion, as well as recruitment 
of cytosolic LC3 to autophagosomes, are widely used 
as reliable markers of autophagic activity. The ATG12-
ATG5-ATG16L1 complex is thought to act as an E3-like 
enzyme for LC3 lipidation, creating a direct link and 
interdependency between the 2 systems (Otomo et al., 
2013). LC3 lipidation is necessary for the elongation and 
completion of autophagic vesicles. Moreover, LC3 proteins 
Figure 1. Key morphological steps of autophagy in mammals. After mTOR inhibition (for example, with energy depletion, 
starvation, or hypoxia), the autophagy process begins with the nucleation of the isolation membrane. The 2 ubiquitin-like 
conjugation systems ATG16L1-ATG5-ATG12 and LC3-II participate after their activation in the expansion of the double 
membrane and the closure of the isolation membrane. Once it is completed, the structure is called an autophagosome. In 
mammalian systems, the autophagosome may fuse with a late endosome to form an amphisome, or it may fuse directly 
with a lysosome to form an autolysosome. Once the cargos are degraded, the products are released to the cytosol to be 
reused by the cell. 
LAMP%
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As mentioned earlier, the class III PI3K members are necessary for the 
formation of the autophagosome, in which two conjugation systems are 
necessary (figure 1.4). The first system includes Atg5, Atg12 and Atg16L1. 
The linkage of Atg12 and Atg5 proteins is mediated by Atg7 (an E1 activating 
enzyme) and Atg10 (an E2 conjugating enzyme) (Geng & Klionsky 2008).  
The Atg12-Atg5 complex, interacts with Atg16L1 to form Atg12-Atg5-Atg16L1 
complex (Ohsumi & Mizushima 2004) (figure 1.3). This complex localizes to 
the phagophore, thereby enabling the elongation process (Suzuki et al. 2007) 
(figure 1.4). 
  
The second system involved in the expansion of the pre-autophagosome 
structure is LC3-PE (phosphatidylethanolamine) (Suzuki et al. 2001; Suzuki 
et al. 2007).  The precursor protein LC3 is cleaved by the cysteine-protease 
Atg4B thus generating LC3-I.  LC3-I is then activated by Atg7 and transferred 
to Atg3, a conjugating enzyme (Nakatogawa et al. 2012). The Atg12-Atg5-
Atg16L1 complex facilitates the LC3-PE complex by conjugating LC3-I to PE 
thus generating LC3-II (Mizushima et al. 1999; Mizushima et al. 2003).  LC3-
II is frequently used to monitor the process of autophagy due to its 
localization on the outer and inner autophagosome membrane and 
association with the autophagosome (figure 1.4).  
  
The autophagosome undergoes a first process regulated by the small 
GTPase Rab7 before fusion with the lysosome (Gutierrez et al. 2004). The 
second and final process involves fusing the autophagosome with the 
lysosome/endosome and this process is mediated by LAMP (lysosome –
associated membrane protein) (figure 1.4). Fusion of the autophagosome to 
the lysosome results in autolysosome wherein hydrolytic enzymes such as 
cathepsins B, D and L degrade sequestered material (He & Klionsky 2009). 
The amino acids and lipids generated by the lysosomes can be used as an 
energy source and building blocks especially in starvation conditions 
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 1.3.2.3 The role of autophagy in cancer 
 
Autophagy seemingly has dual roles in cancer because of its role in cell 
survival and cell death processes (White & DiPaola 2009). Depending on the 
stage of cancer, autophagy can be a tumour suppressor mechanism at the 
early stage of cancer or promote tumourigenesis (Brech et al. 2009).    
 
Autophagy can act as a tumour suppressor mechanism based on its frequent 
down-regulation in tumours (Inguscio et al. 2012). Beclin1 has been 
extensively reported as a tumour suppressor due to the allelic deletion of the 
gene encoding Beclin1 BECN1 in human ovarian, breast and prostate cancer 
(Shimizu et al. 2004). Moreover, many studies have demonstrated that mice 
with Beclin1 mutations were prone to tumours, suggesting the tumour-
suppressing role of Beclin1 (Qu et al. 2003; Yue et al. 2003). Beclin1 can 
also interact with endophilin B1 (Bif-1) and act as a tumour suppressor. The 
interaction of Beclin1 with Bif-1 via UVRAG activates Vps34 resulting in the 
formation of autophagosome.  Loss of Bif-1 is often associated with a wide 
variety of human cancer such as gastric carcinoma, colorectal carcinoma and 
urinary cancer (Ionov et al. 2004; Takahashi et al. 2005).  
 
Autophagy has also been implicated in cell survival processes in various 
cancer cells (Inguscio et al. 2012). Due to its role in supplying nutrients from 
cytoplasmic breakdown, autophagy can enable metastasized cancer cells to 
tolerate stressful conditions, hypoxia, nutrient deprivation and the effect of 
anti-cancer drugs such as cisplatin and camptothecin (Lock & Debnath 
2008). Interestingly, knockdown or genetic inhibition of important autophagy 
role-players such as Atg5 or beclin1 in cancer has been shown to induce 
autophagy cell death (White & DiPaola 2009).  
 
Understanding the function of autophagy in tumourigenesis is crucial since 
some anticancer drugs and pharmacological agents have been reported to 
induce autophagy (Shen, 2014; Wong et al. 2013). Moreover, autophagy can 
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either promote survival or death in cancer cells as discussed above. It seems 
that the specific role of autophagy (cell death or cell survival) in cancer 
depends on treatment, tissue and is specific to the type of cell line. In 
addition, several pathways have been involved in the activation of 
autophagy. Some of those pathways will be discussed in the next section.    
 
1.3.2.4 The regulation of autophagy  
   
Multiple signaling pathways regulate autophagy, presumably reflecting the 
critical nature of autophagy in cell survival, in conditions of crisis, and in 
mediating cell death. These signaling pathways include: (1) PI3K/AKT/mTOR 
(2) AMPK/TSC/mTOR and (3) ER stress/Ca2+/CAMMK/AMPK/mTOR.   
  
The mTOR pathway includes two complexes: mTORC1 and mTORC2. 
mTORC1 complex has been reported to be involved in autophagy and 
consists of mTOR, PRAS40 (proline rich AKT substrate of 40kDa), RAPTOR 
(regulatory associated protein of mTOR) and mLST8 (mammalian lethal with 
sec-thirteen protein 8, also known as GβL) (Gwinn et al. 2008; Inoki et al. 
2003; Wullschleger et al. 2006). The PI3K-AKT-mTOR pathway constitutes 
the inhibitory pathway controlling autophagy and is activated by the binding 
of the insulin-like growth factor (IGF) to the insulin receptor (IR) resulting in 
the activation of PI3K (figure 1.5). Activated PI3K converts 
phosphatidylinositol-3,4-bisphosphate, phosphatidylinositol-4,5 bisphosphate 
(PIP2) to phosphatidylinositol-3,4,5 trisphosphate (PIP3). This then causes 
phosphoinositide-dependent kinase (PDK1) and AKT to the recruited at the 
cell membrane. Phosphorylated and activated AKT results in the inhibition of 
the TSC1/2 complex (Tuberous sclerosis factor 1 and 2) by phosphorylation 
of TSC2 (Alessi et al. 1997; Stokoe et al. 1997). Inhibited TSC1/2 complex 
activates the small GTPase Rheb (Ras Homolog Enriched in Brain), which in 
turn is able to activate mTOR, resulting in the inhibition of autophagy. PTEN 
(Phosphotase and tensin homolog deleted on chromosome 10) stimulates 
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autophagy by inhibiting the PI3K/AKT pathway (Arico et al. 2001) (figure 1.5).  
 
Metabolic and energy stress induces autophagy through the activation of the 
AMPK-mTOR pathway in mammalian cells. In these cells, AMPK (AMP-
activated protein kinase) phosphorylates and activates the TSC1/2 complex, 
allowing the phosphorylation of TSC2 by GSK-3β (glycogen synthase kinase 
3). Phosphorylation of TSC2 results in the inhibition of the mTOR through the 
small GTPase Rheb (figure1.5) (Inoki et al. 2003; Shang & Wang 2011).    
 
ER stress is also responsible for calcium release from the ER into the 
cytoplasm, which results in the phosphorylation and activation of calcium-
activated calmodulin-dependent kinase kinase-β (CaMKKβ), leading to the 















    
Figure 1.5: Pathways involved in the regulating of autophagy. The PI3K-AKT-
mTOR pathway blocks the autophagy process. AMPK activates autophagy by 
phosphorylating and activating the TSC1/2 complex. This complex inhibits the 
mTOR pathway and can also be activated by calcium (CAMKKβ) (Adapted from 
Ravikumar et al. 2010). 
  
Numerous studies support the idea that autophagy is induced by ER stress in 
mammalian cells (Yorimitsu et al. 2006; Younce & Kolattukudy 2010). ER 
stress can be induced by various factors that include treatment with 
accumulation of misfolded proteins, hypoxia, a decrease in glucose and 
chemotherapeutic agents (Høyer-Hansen & Jäättelä 2007). Once the ER 
stress occurs, the unfolded protein response (UPR) is induced to alleviate 
the stress by either inhibition of protein synthesis or upregulation of protein 
folding and degradation pathways. Three pathways regulate the UPR: the 
activating transcription factor 6 (ATF6), inositol requiring enzyme 1 (IRE1) 
and PRK (RNA-dependent protein kinase) - like ER kinase (PERK) (Ogata et 
al., 2006 (figure 1.6). Studies showed that treatment of mouse embryonic 
fibroblasts (MEFs) and cancer cells with tunicamycin activated the 
Many diverse signals, such as growth factors, amino
acids, glucose, energy status, and different forms of
stress, regulate the raptor-mTOR (mTORC1) pathway
(445). The activity of mTORC1 can be inhibited by rapa-
mycin (sirolimus), a lipophilic macrolide antibiotic first
isolated from Streptomyces hygroscopicus (145, 365).
Rapamycin i a potent autophagy inducer in various cell
lines from yeast to mammalian cells, including neurons
(28, 365, 415, 416, 427). In mammalian cells, rapamycin
forms a complex with the immunophilin FK506-binding
protein of 12 kDa (FKBP12), which then stabilizes the
raptor-mTOR association and inhibits the kinase activity
of mTOR (228). The binding of G!L to mTOR stimulates
its kinase activity, and G!L is necessary for the formation
of a rapamycin-sensitive interaction between raptor and
mTOR (229). Inhibition of mTORC1 and induction of au-
tophagy by rapamycin is associated with reduced phos-
phorylation of two of its downstream effectors, ribosomal
protein S6 kinase-1 (S6K1, also known as p70S6K) and
translation initiation factor 4E binding protein-1 (4E-BP1,
FIG. 2. The phosphatidylinositol 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) pathway regulating autophagy. The PI3K pathway is
triggered by the binding of insulin (or growth factors) to insulin receptor (IR), thereby activating PI3K. Activated PI3K converts PIP2 to PIP3, which
then recruits phosphoinositide-dependent kinase 1 (PDK1) and Akt to the cell membrane. Akt is then phosphorylated and activated, which in turn
phosphorylates and inactivates tuberous sclerosis complex (TSC) 1/2, leading to activation of Rheb and consequently mTORC1. Akt can also be
phosphorylated and activated by mTORC2. AMPK, a cellular energy sensor of changes in the intracellular ATP/AMP ratio, directly phosphorylates
TSC2, thereby providing the priming phosphorylation for subsequent phosphorylation of TSC2 by glycogen synthase kinase 3 (GSK3) to inhibit
mTORC1 signaling. The mTOR pathway involves two functional complexes: a rapamycin-sensitive mTORC1 that regulates autophagy, consisting of
the mTOR catalytic subunit, raptor, mLST8, and PRAS40; and mTORC2 comprising of mTOR, rictor, mLST8, SIN1, and PROTOR. Amino acids
activate mTORC1 via Rag GTPases and suppress autophagy. The rate-limiting factor of amino acid signaling is L-glutamine, which is initially taken
up by its high-affinity transporter SLC1A5, followed by its efflux by the SLC7A5/SLC3A2 bidirectional transporter in exchange for uptake of essential
amino acids, which subsequently activates mTORC1. The ULK1-Atg13-FIP200 complex acts as an integrator of the autophagy signals downstream
of mTORC1. Under nutrient-rich conditions, mTORC1 suppresses autophagy by interacting with this complex and mediating phosphorylation-
dependent inhibition of Atg13 and ULK1. Under starvation conditions or rapamycin treatment, mTOR dissociates from the complex, resulting in
dephosphorylation-dependent activation of ULK1 and ULK1-mediated phosphorylations of Atg13, FIP200, and ULK1 itself, which triggers autophagy.
The mTORC1 pathway regulates cell growth mainly through 4E-BP1 and p70S6K. Phosphorylation-dependent activation of p70S6K can also inhibit
IRS1, thereby exerting a feedback loop mechanism.
1392 RAVIKUMAR ET AL.
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phosphorylation of c-Jun N-terminal (a downstream target of the IRE1 
pathway), which then leads to autophagy (Ding et al. 2007; Ogata et al. 
2006). Other studies conducted on murine cells reported that the expression 
of misfolded polyQ72 or mutant dyferlin proteins induced ER stress, leading 
to the phosphorylation of eIF2α (a downstream target of PERK). This 
resulted in the conversion of LC3 and the degradation of the mutant proteins 
within the ER organelle (Fujita et al. 2007). These studies concluded that the 
IRE1 and PERK pathways play important roles in UPR-induced autophagy.  
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Figure 1.6 Relationship between the ER stress pathways and autophagy. The 
three ER stress sensors are held inactive by the GRP78 proteins. When the 
unfolded proteins accumulate, the GRP78 dissociates from the sensors, resulting in 
their activation. The PERK and IRE1 have been implicated in autophagy. In the 
IRE1 branch, BCL2 is phosphorylated by JNK, which result in the release of BCL2 
from Beclin1, thus activating autophagy. In the PERK branch, ATF4 and CHOP 
cause the upregulation of LC3B, ATG12 and ATG5 (Aronson & Davies 2012). 
   
Studies have implicated ROS as an intracellular stressor that induces 
autophagy. It has been reported that excessive ROS generation upon 
treatment with anticancer agents leads to autophagic cell death (Yu et al. 
2006).  
Section 1.3 described the PCD that cancer utilizes to maintain cell 
homeostasis, development as well as survival. When these PCDs are 
disrupted, cancer occurs. Cells contain a variety of death pathways; an 
understanding and manipulation of these pathways by anticancer agents 
may help in fighting the disease 
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 A diverse range of anticancer drugs are currently utilized for the treatment of 
various cancers. However, these chemotherapeutic agents are often 
associated with unwanted toxicity. Therefore, there is a need to develop 
novel anticancer compounds that can specifically targeted cancer cells while 
sparing normal cell.  Novel anticancer agents employed to target cells elicit 
their effect by manipulating the PCD’s previously described. Generally the 
preferred PCD chosen by researchers is PCD II or apoptosis, although this 
causes a limitation in the understanding of other PCD such as autophagy.  
Cancer cells are often resistant to chemotherapeutic treatment, and therefore 
exploiting or developing compounds that can target and activate more that 
one programmed cell death will help in improving cancer treatment. Until 
now, the main interest in cancer research has been to improve therapies by 
determining either the effect of newly discovered anticancer drugs or various 
drugs effective against other diseases. The artemisinins represent a family of 
compounds with great potential that can be used as source for novel 
anticancer compounds.  Moreover, a possible role of artemisinin derivatives 
in overcoming drug-resistant cases has also been reported (Enzinger & 
Mayer 2003; Gottesman 2009)  
  
On the basis of these remarkable features, dihydroartemisinin the most 
potent artemisinin compound was covalently conjugated to isatin an indole 
derivative by the chemistry department of the University of Cape Town. The 
final product was a novel isatin-artemisinin derivative named EXP57EA. In 
this study we explored the activity of this novel compound to kill cancer cells 
and to understand the mechanism of cell death as a follow on of earlier 
studies performed in our laboratory.      







1.4    Project Aim and Objectives 
Determine the effect of EXP57EA on a panel of cancer cell lines by, 
(1) Comparing the cytotoxicity effect of EXP57EA, DHA and Cisplatin
(2) Determining the mode of cell death caused by EXP57EA on a panel of
selected cancer cell lines and
(3) Investigating the signaling pathways triggered by EXP57EA in WHCO1
and WHCO5 cell lines.
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2.1    Determine the cytotoxicity of artemisinin derivatives  
   
Artemisinins and its derivatives have been widely used in the treatment of 
malaria for several years (Maria P Crespo-Ortiz & Wei 2012), and recently 
this family of compounds was shown to have antiviral and antimicrobial 
activities as well as strong anticancer activity in vivo and in vitro. A study 
conducted by Xu et al., in 2011 demonstrated that the artemisinin derivative 
artesunate may be used as a chemotherapeutic agent in highly metastatic 
and aggressive cancers in vitro and in vivo (Xu et al. 2011). Colleagues from 
the Chemistry Department at the University of Cape Town designed a novel 
hybrid compound, by covalently conjugating the most potent artemisinin 
compound Dihydroartemisinin (DHA) with an iodo-isatin azide intermediate 
compound using click chemistry and a novel hybrid compound was 
generated, namely EXP57EA (figure 2.1). The strategy behind the design of 
compound EXP57EA is discussed in a previous thesis (Shunmoogam-
Gounden 2014).      
  
 















Figure 2.1: Structure of EXP57EA. Structures showing the two compounds that 
were covalently conjugated to form the novel artemisinin-isatin hybrid compound. 	  
	  	  	  
	  
The results presented in this section examined the cytotoxic effect of the novel 
hybrid compound EXP57EA compared to the parental compound DHA, which 
has been reported to be the most potent artemisinin-like compound (Maria P. 
Crespo-Ortiz & Wei 2012). Moreover, the cytotoxic effect of cisplatin, a drug 
commonly used as single or combination therapy in the treatment of various 
cancers was also compared to that of the novel hybrid compound.    
  
The cytotoxicity of DHA, EXP57EA and cisplatin was determined on a panel 
of cancer cell lines including three esophageal cancer (OC) cell lines 
WHCO1, WHCO5 and KYSE150 which are routinely used as model 
esophageal cancer cell lines in our laboratory (Hadley & Hendricks 2014; 
Van Der Watt et al. 2014), one metastatic breast cancer cell line MDA-MB-
231 and one cervical cancer cell line SiHa. For the cytotoxicity assay, cell 
number was estimated using the MTT (3 [4, 5-dimethylthiazol-2-yl] -2, 5-
diphenyltetrazolium bromide) assay and GraphPad prism software was used 
to generate dose response curves and IC50 values (concentration of the drug 




2.2.4 Structure-activity analysis of EXP57EA 
The novel artemisinin-isatin hybrid, EXP57EA, was the most active novel compound tested 
in this study. In addition, we observed that this novel compound displayed activity against 
cells insensitive to ART and DHA, the first generation artemisinin derivatives. EXP57EA, 
distinguished from the other novel artemisinin-isatin hybrid compounds by the iodine side 
chain, was synthesized via covalent linkage of the dihydroartemisinin intermediate compound 
(IM1, Figure 2.7) to the iodo-isatin azide intermediate compound (IM2, Figure 2.7) using 
‘click’ chemistry (Hans, 2009). Each of the intermediates involved in the synthesis of 
EXP57EA was tested for activity against WHCO1 and WHCO6 OC cells (Table 2.4). 
 
 
Figure 2.7: General structure showing design of EXP57EA. The chemical structure of EXP57EA illustrating 
the intermediate compounds that were covalently linked to form the artemisinin-isatin hybrid.  
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Screening EXP57EA against the panel of cancer cell lines showed that 
EXP57EA displayed activity across all cell lines. EXP57EA was more active 
in WHCO1 915.8 µM) and WHCO5 (20 µM) than in KYSE150 (29.2 µM), 
MDA-MB-231 (22.1 µM) and SiHa (25.1 µM) (table 2.1). EXP57EA was more 
active across all cell lines compared to DHA, which in turn was active against 
two cell lines: the esophageal cancer cell lines: WHCO1 (21.3 µM) and 
WHCO5 (77.3 µM). DHA displayed no cytotoxicity in KYSE150, MDA-MB-
231 and SiHa cell lines in the concentration range tested (0 µM – 200 µM)  
(table 2.1). It was reported that MDA-MB-231 and SiHa cell lines are 
resistant to certain chemotherapeutic agents including cisplatin (Yde & 
Issinger 2006) and this was confirmed in this study where DHA was not 
active in MDA-MB-231 and SiHa. Here, cisplatin displayed decreased 
sensitivity to the same cell lines.  
 
Cisplatin was less active in OC cell line WHCO1 with an IC50 value of 48.5 
µM compared to DHA, with an IC50 value of 21.3 µM. However, cisplatin was 
more active in WHCO5 (31.2 µM), KYSE150 (86 µM), MDA-MB-231 (108.1 
µM) and SiHa (71.1 µM) cell lines than DHA (table 2.1). It was also found that 
the novel hybrid compound EXP57EA was more active than cisplatin across 
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Figure 2.2: IC50 curves showing sensitivity of WHCO1 cells to DHA, EXP57EA 
and cisplatin. Cells were plated at a density of 3000 cells per well in 96 well plates 
and were treated with a range of concentrations of EXP57EA for 48 hours, followed 
by MTT assay. The absorbance was read on a plate reader at 595 nm and data 
were analyzed using GraphPad software. Each point was performed in triplicate and 
error bars represent the mean ±SD. These figures are representative of three 













   
!IC50 = 31 µM  
 95% CI = 24-39.9   
    
IC50 = 12 µM  
95% CI = 8.6-16.7 
!IC50 = 23 µM 
 95 % CI = 14.2-35.5  
   
	  
	   33	  
Table 2.1:  IC50 values of EXP57A, DHA and cisplatin in a panel of cancer cell 
lines.  The IC50 values obtained for EXP57EA, DHA and cisplatin screened against 
three esophageal cancer cell lines WHCO1, WHCO5 and KYSE150, one breast 
cancer cell line MDA-MB-231 and one cervical cancer cell line SiHa. The MTT 
assay was used to measure cell number and GrapPad software was used to 
calculate the global IC50 values and the 95 % confidence interval. 
	  	  
	  	  	  	  	  	  	  *NA	  =	  Not	  active	  
	  
The purpose of synthesizing novel hybrid compounds is to produce 
compounds that displayed better activity than their parental compounds 
(Meunier et al. 2010). The results in this project showed that this has been 
achieved where EXP57EA displayed greater activity than DHA and cisplatin 
in all cell lines tested. Hybrid compounds have been reported to be 
pharmacologically different from their parental compounds by displaying 
different or better activity from their parental compound (Teiten et al. 2014).	  	  
Considering that earlier studies performed in our laboratory suggested that 
EXP57EA induced autophagy, we investigated the mode of cell death 
IC50 values (µM) and 95 % Confidence interval 
(CI) 
DHA Cisplatin EXP57EA 
WHCO1 
 21.3    
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mediated by EXP57EA, using this compound at 15 µM based on the 
outcome of the experiments reported in table 2.1.  	  









	  	  	  
	  	  
	  
	  	  	  
	  	  
	  	  






2.2    The effect of EXP57EA on cultured-cancer cell morphology  
Previous studies have shown that DHA induced apoptosis in various cancer 
cell lines (Hou et al. 2008; Lu et al. 2014). It was shown in our laboratory that 
esophageal cancer cell lines WHCO1 and WHCO6 treated with 60 µM DHA 
for 48 hours, displayed the morphological changes indicative of apoptosis. 
Nuclear condensation and shrinkage of the cytoplasm were observed, later 
confirmed by PARP cleavage and caspase activity assays (Shunmoogam-
Gounden 2014).  However, in that study when the same cell lines were 
treated with EXP57EA, the morphological features were not consistent with 
apoptosis. Instead after 24 hours and 48 hours treatment, numerous 
intracellular, perinuclear vacuoles were observed using transmission electron 
microscopy (TEM) and these changes occurred in a time and dose-
dependent manner.  
To understand how EXP57EA causes cell death, the cancer cell lines 
previously mentioned were treated with 15 µM EXP57EA for 24 hours and 
the morphology of cells were observed using a microscope (figure 2.3). The 
morphological changes of cells treated with EXP57EA showed various 
intracellular vacuoles (white arrows). Interestingly WHCO5, KYSE150, MDA-
MB-231 and SiHa cells showed signs of autophagy (vacuoles), even though 
the IC50 value of EXP57EA in these cell lines were higher than the WHCO1 
cell line. When WHCO1 and WHCO5 cells were treated with 40 µM DHA, cell 
shrinkage was observed in the treated cells compared to the control, which 
was indicative of apoptosis. Interestingly, even though KYSE150, MDA-MB-
231 and SiHa cells were resistant to DHA, cell shrinkage was seen when the 
cells were treated with 75 µM DHA, also indicative of apoptosis (figure 2.4).  
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Figure 2.3: The effect of EXP57EA on cell morphology. Cells were plated at a 
density of 300000 cells per 60 mm dish.  (A) Cells were treated with DMSO (control) 
and  (B) 15 µM EXP57EA for 24 hours. After the indicated time, images of the cells 
     CONTROL 
     !!!!!!WHCO1 
          EXP57EA (15µM) 
     !!!  WHCO5 
     !! MDA-MB-231 
     !!!!!!!!!!SiHa 
     !!!! KYSE150 
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were captured with a Primovert inverted microscopy with an Axio cam ERC 5s 
(Zeiss, Göttingen, Germany). White arrows point out intracellular vacuoles. 
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Figure 2.4: The effect of DHA on cell morphology. Cells were plated at a density 
of 300000 cells per 60 mm dish.  (A) Cells were treated with DMSO (control) and  
(B) WHCO1 and WHCO5 were treated with 40 µM, MDA-MB-231, KYSE150 and 
SiHa were treated with 75 µM DHA for 24 hours. After the indicated time, images of 
!!!!!!!!!!!!MDA-MB-231 
        WHCO1 
             CONTROL                      DHA   
     !!!WHCO5 
     !!      SiHa 
!!!!!!!!!!!!KYSE150 
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the cells were captured with a Primovert inverted microscopy with an Axio cam ERC 
5s (Zeiss, Göttingen, Germany). White arrows point out cell shrinkage. 
  
The effect of EXP57EA and its parental compound DHA on cell morphology 
was examined. The results showed that EXP57EA treatment was associated 
with the appearance of intracellular vacuoles, suggestive of autophagy. 
When cells were treated with DHA, cell shrinkage was observed, confirming 
previous results found in our laboratory.  
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2.3    Investigate the mode of cell death caused by EXP57EA in the 
panel of cancer cell lines   
  
The mechanisms by which most anticancer agents cause death is important 
since there is a general view that apoptosis is the preferred mechanism of 
cell death in the context of chemotherapeutic treatment of cancer. Moreover, 
it is the most well characterized mode of cell death (Du et al. 2013). 
  
In order to determine the mode of cell death induced by EXP57EA in the 
panel of cancer cell lines used here, a PARP (Poly ADP-ribose polymerase) 
assay was done. PARP is a well-known caspase substrate and its cleavage 
in two fragments (116 kDa and 85 kDa) is frequently used as a marker of 
apoptosis (Casao et al. 2015; Chaitanya et al. 2010).  PARP cleavage was 
examined by western blot in WHCO1, WHCO5, KYSE150, MDA-MB-231 and 
SiHa cells treated with 15 µM EXP57EA for 24 hours.  WHCO1 cells were 
treated with 15 µM Doxorubicin (DOX) and used as a positive control for 
PARP cleavage. GAPDH was used as a loading control.  Cell lines treated 
with EXP57EA showed no PARP cleavage, however WHCO1 treated with 
Dox showed PARP cleavage after 24 hours treatment (figure 2.5.A). 
Furthermore, when the same cell lines were treated with DHA for 24 hours 
(concentrations mentioned in above section), PARP cleavage was clearly 
seen in all cell lines (figure 2.5.B). These results showed that EXP57EA did 
not activate PARP cleavage; instead, its parental compound DHA activated 
PARP cleavage in all cell lines tested. Moreover, these results confirmed the 
morphological changes observed in figure 2.3 where no clear signs of 
apoptosis was seen, instead vacuoles were observed which was suggestive 











Figure 2.5: Effect of EXP57EA and DHA on PARP cleavage. Cells were plated at 
a density of 300000 cells per 60 mm dish.  (A) The cells were treated with 15 µM 
EXP57EA and (B) WHCO1 and WHCO5 were treated with 40 µM, MDA-MB-231, 
KYSE150 and SiHa were treated with 75 µM DHA for 24 hours. Proteins were 
harvested and 20 µg were separated on a 10 % SDS-PAGE and proteins were 
transferred to a nitrocellulose membrane.  WHCO1 cells were treated with 15 µM 
DOX for 24 hours and used as a positive control for PARP cleavage (A). GAPDH 
was used as a loading control. This result is representative of two independent 
experiments. 
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We performed further experiments to determine if EXP57EA induced 
autophagy, since treatment of cells with this compound induced the 
appearance of vacuoles that resembled autophagic vesicles and failed to 
induce PARP cleavage (figures 2.3 and 2.5). We used two traditional 
autophagy markers LC3-II and Beclin1, both involved in autophagy. The 
aberrant expression of these two markers has been reported in various 
cancers including melanoma, human colon, ovarian, lung and brain cancer 
(Aita et al. 1999; Miracco et al. 2007; Yorimitsu & Klionsky 2007). To this 
end, western blot analysis was performed to examine the expression level of 
Beclin1, upon EXP57EA treatment. Figure 2.6 showed western blot results of 
the expression level of Beclin1 after 12 hours and 24 hours treatment. 
Changes in the expression level of Beclin1 were seen at both 12 hours and 
24 hours in all cell lines, however, at 24 hours the expression level of Beclin1 
consistently decreased in all cell lines. These results suggested that 
EXP57EA treatment activates Beclin1.   	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Figure 2.6: Beclin1 expression after treatment with EXP57EA. Cells were plated 
at a density of 300000 cells per 60 mm dish. The cells were treated with 15 µM 
EXP57EA for 12 hours and 24 hours. Proteins were harvested and 40 µg were 
separated on a 10 % SDS-PAGE and proteins were transferred to a nitrocellulose 
membrane. The membrane was probed with an antibody recognizing Beclin1. 
GAPDH was used as a loading control and this figure is representative of three 
independent experiments. 	  
	  	  	  
	  
To further confirm that EXP57EA plays a role in the induction of autophagy, 
the effect of EXP57EA on LC3-II expression levels was also examined by 
western blot. LC3 protein consists of two forms: the soluble form LC3-I, with 
a size of 18 kDa and a lipidated form LC3-II, with an apparent size of 16 kDa. 
Figure 3.7 shows the expression level of LC3-II in the same panel of cancer 
cell lines, in response to EXP57EA treatment. Treatment with 15 µM 
EXP57EA caused the activation of LC3-II at 12 hours and 24 hours in 
WHCO1, WHCO5, KYSE150 and MDA-MB-231 cell lines  (figure 2.7). 
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However, in SiHa treated cells, both at 12 hours and 24 hours, the 
expression level of LC3-II was low compared to untreated cells. It has been 
reported that the expression level of LC3-II and Beclin1 protein was 
significantly decreased in cervical squamous cancer cells than in healthy 
squamous epithelial cells. This suggests that autophagy may play a tumour-
suppressing role in cervical tumourigenesis (Orfanelli et al. 2014).  
  
Our results, which show clear changes in the level of Beclin1 and LC3-II in 
response to EXP57EA treatment, strongly suggested that this compound 
induces autophagy. However, these results could also reflect a blockage in 
the fusion of the autophagosome with the lysosome, resulting in the 
accumulation of autophagosomes or a deficiency in the lysosomal 
degradation step, also resulting in the accumulation of autolysosomes 
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Figure 2.7: LC3-II expression after treatment with EXP57EA. Cells were plated 
at a density of 300000 cells per 60 mm dish. The cells were treated with 15 µM 
EXP57EA for 12 hours and 24 hours. Proteins were harvested and 40 µg were 
separated on a 15 % SDS-PAGE and proteins were transferred to a nitrocellulose 
membrane. The membrane was probed with an antibody recognizing LC3-I and 
LC3-II. GAPDH was used as a loading control and this figure is representative of 
three independent experiments.  
	  	  
In this study, we monitored the activation of autophagy by measuring LC3-II 
levels in cells. However, autophagy is a multi-step process and changes in 
Beclin1 and LC3-II levels could be indicative of a blockage in the autophagic 
process, and not increased autophagic flux. Therefore, the detection of the 
number of autophagosomes and the assessment of LC3-II by microscopy 
and immunoblotting respectively are insufficient to conclude if a particular 
compound activates autophagy (Zhang et al. 2013). There are however, 
standard methods available to determine whether a particular compound 
activates autophagy. Among these, is the measurement of autophagic flux by 
analyzing LC3-II turnover by western blot. This method is based on the 
observation that LC3-II is degraded in the autolysosome during autophagy 
(Mizushima et al. 2010).  
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During the process of autophagy, lysosomal enzymes degrade the cargo 
within the autophagosome after fusion of the autophagosome with the 
lysosome to form the autolysosome. Thus, lysosomal enzymes may degrade 
considerable amounts of endogenous LC3-II on autophagosomes. To 
investigate lysosomal LC3-II turnover, we employed ammonium chloride 
(NH4Cl) and chloroquine. Both compounds block the lysosomal degradation 
of the autolysosome content by inhibiting the Na+ /H+ pump, raising the 
lysosomal pH and therefore inhibiting acidic lysosomal proteases 
(Rubinsztein et al. 2009). Cells were pretreated with 10 mM NH4Cl and 30 
uM chloroquine for 1 hour. Figure 2.8 showed that when WHCO1 and SiHa 
cells were co-treated with EXP57EA and NH4Cl a significant increase in the 
expression level of LC3-II was observed compared to cells treated with 
EXP57EA alone (figure 2.8). When chloroquine was used in WHCO1 cells, 
the expression level of LC3-II increased significantly in the cells co-treated 
with EXP57EA and chloroquine compared to cells treated with EXP57EA 
alone. Klionsky et al. 2016 reported that Increased level of LC3-II in the cells 
treated with the inhibitor is indicative of autophagic flux carrier to the 
lysosome (Klionsky et al. 2016) This was confirmed in this study where 
WHCO1 cells treated with chloroquine alone displayed an increased level of 
LC3-II. The results showed that EXP57EA increased the synthesis of the 
autophagosomes and delivery of substrates to the lysosomes.  Based on 
these results we can conclude that EXP57EA increased the autophagic flux 
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Figure 2.8:  The effect of NH4Cl and chloroquine on LC3-II accumulation.  
WHCO1 and SiHa Cells were plated at a density of 300000 cells per 60 mm dish. 
Treatments were as follows: cells were pre-treated for 1 hour with either 10 mM 
NH4Cl or 30 µM chloroquine. After 1 hour, the cells were treated with 15 µM 
EXP57EA for 24 hours.  Control cells were treated with DMSO. Proteins were 
harvested and 40 µg were separated on a 15 % SDS-PAGE and proteins were 
transferred to a nitrocellulose membrane. The membrane was probed with an 
antibody recognizing LC3-I and LC3-II. GAPDH was used as a loading control and 
this figure is representative of two independent experiments. 
	  
Having shown that EXP57EA activated autophagy on the basis of (1) 
changes in the expression level of two important autophagy markers; LC3-II 
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and Beclin1; (2) increased autophagic flux as well as showing that EXP57EA 
did not activate PARP, we next investigated the underlying pathways 
involved in EXP57EA-activated autophagy.   
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2.4    Investigating the cellular signaling pathway activated by EXP57EA 
in a panel of cancer cell lines 
  
In the previous two sections, we showed that EXP57EA displayed activity 
against the cancer cell lines tested and that EXP57EA was more active than 
DHA and cisplatin when screened against the same cell lines. Further 
investigations showed that EXP57EA activates autophagy and not apoptosis. 
Various studies on the anticancer effect of artemisinin derivatives have been 
extensively reported in various cancer cell lines. The next section will attempt 
to investigate the underlying signaling pathways activated by EXP57EA 
leading to autophagy.    
 
Various studies have been reported that increased levels of ROS can lead to 
the induction of autophagy via the JNK pathway, as well as the ER stress 
pathway through one of its downstream targets PERK (Chen et al. 2009; X. 
Li et al. 2013). Previous work in our laboratory showed ROS production. In 
that study, the involvement of O2-   in mediating the effect of EXP57EA on 
cancer cells was demonstrated. It was also shown that tempol (a scavenger 
of O2- ) inhibited the effect of EXP57EA on cancer cells. In this present study, 
we wanted to determine the effect of EXP57EA on the PERK/eIF2α/CHOP 
signaling pathway that has been shown to be triggered by O2- production.  
 
WHCO1 cells were plated in 60 mm dishes. After 24 hours, cells were 
treated with EXP57EA in the presence and absence of tempol.  Figure 2.9 
shows the effect of EXP57EA on the PERK/eIF2α pathway.   WHCO1 cells 
treated with 5 µM EXP57EA in the presence and absence of tempol did not 
have any effect on the expression level of p-eIF2α (figure 2.9). In general, the 
expression level of p-eIF2α was the same in the presence and absence of 
tempol in WHCO1 cells treated with 5 µM EXP57EA. However, treatment of 
WHCO1 cells with 15 µM EXP57EA in the absence of tempol stimulated the 
phosphorylation of eIF2α, but in the presence of tempol, phosphorylation of 
eIF2α was substantially reduced (figure 2.9).  
	  






    
Figure 2.9: The effect of EXP57EA on p-eIF2α level in WHCO1 cells in the 
presence and absence of tempol.  WHCO1 cells were plated at a density of 
300000 cells per 60 mm dish. Cells were pre-treated with 0.25 mM tempol or DMSO 
(control) for 1 hour followed by treatment with 5 µM and 15 µM EXP57EA for 24 
hours. Protein was harvested then 40 µg were separated on a 10 % SDS-PAGE and 
proteins were transferred to a nitrocellulose membrane. The membranes were 
probed with an antibody recognizing p-eIf2α and total eIf2α. GAPDH was used as a 
loading control and this figure is representative of two experiments.    
	  
  
PERK is a downstream target of the ER stress pathway that has been 
reported to be involved in the induction of autophagy through the activation of 
the transcription factor C/EBP homologous proteins (CHOP) (Shen, Zhang, 
Wang, et al. 2014b). Consequently, we wanted to see if EXP57EA treatment 
increases the expression level of CHOP. Real-time PCR (RT-PCR) was used 
to examine the mRNA expression level of CHOP (standardized to the 
housekeeping gene GusB) upon EXP57EA treatment. Untreated cells 
(control) were incubated with DMSO and all the values were relative to the 
control value. A significant increase in CHOP mRNA expression level was 
observed in WHCO1, WHCO5, MDA-MB-231 and SiHa cell lines upon 24 
hours EXP57EA treatment. However, no significant increase in the mRNA 
expression level of CHOP was seen in KYSE150 cell line due to 
discrepancies in Ct values (figure 2.10). Based on these results, it was 
concluded that CHOP levels were significantly elevated in response to 
EXP57EA treatment in WHCO1, WHCO5, MDA-MB-231 and SiHa cell lines 
Tempol (mM) 
EXP57EA (µM) 
    GAPDH 
   P-eIF2α 
    eIF2α 
- 0.25  - 0.25 - 0.25 
-  -  5   5  15  15 
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but not in KYSE150 cell line (figure 2.10). Figures 2.9 and 2.10 suggested 
that EXP57EA treatment had an effect on the PERK/eIF2α/CHOP signaling 
pathway, which has been reported to be involved in the induction of 
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Figure 2.10: Evaluation of mRNA levels of CHOP using quantitative real time 
RT-PCR.  Cells were plated at a density of 80000 cells per 60 mm dish. The cells 
were treated with 15 µM EXP57EA for 24 hours. RNA was extracted and messenger 
RNA levels were analyzed by quantitative real time RT-PCR for the gene-encoding 
CHOP. Results (corrected to GusB) are shown relative to the control cells 
(untreated) and are represented as the mean ± SD of experiments performed in 
three independents experiments. p < 0.05. ns = non-significant. 
	  	  	  
  
Mitogen activating protein kinase (MAPK) signaling pathway has also been 
implicated in the induction of autophagy (He & Klionsky 2009; Yu et al. 
2006). We next determined the effect of EXP57EA on the activation of c-jun 
N terminal kinase (JNK), a downstream target of MAPK. The treatment of 
WHCO1 and WHCO5 cells with either 5 µM or 15 µM EXP57EA alone 
stimulated c-jun phosphorylation and resulted in elevated levels of total c-jun 
(figure 2.11 and 2.12 respectively). In the presence of the JNK inhibitor 
SP600125, the expression level of p-c-jun and c-jun decreased in a dose-
dependent manner (figure 2.11 and 2.12 respectively). These results showed 
that the JNK pathway might also be involved in EXP57EA-induced 
autophagy.  
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Figure 2.11:  The effect of EXP57EA on the expression level of p-c-jun and 
level of total c-jun in the WHCO1 cell line in the presence and absence of 
SP600125. WHCO1 cells were plated at a density of 300000 cells per 60 mm dish. 
Cells were pretreated with 10 µM, 25 µM and 50 µM SP600125 or DMSO for 1 hour 
followed by treatment with 5 µM and 15 µM EXP57EA for 24 hours. Protein was 
harvested and 40 µg were separated on a 10 % SDS-PAGE and proteins were 
transferred to a nitrocellulose membrane. The membrane was probed with antibody 
recognizing p-c-jun and total c-jun. GAPDH was used as a loading control and this 
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Figure 2.12:  The effect of EXP57EA on the expression level of p-c-jun and 
level of total c-jun in the WHCO5 cell line in the presence and absence of 
SP600125. WHCO1 cells were plated at a density of 300000 cells per 60 mm dish. 
Cells were pretreated with 10 µM, 25 µM and 50 µM SP600125 or DMSO for 1 hour 
followed by treatment with 5 µM and 15 µM EXP57EA for 24 hours. Protein was 
harvested and 40 µg were separated on a 10 % SDS-PAGE and proteins were 
transferred to a nitrocellulose membrane. The membrane was probed with antibody 
recognizing p-c-jun and total c-jun. GAPDH was used as a loading control and this 
figure is representative of two independent experiments.  
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  CHAPTER 3:   
  
DISCUSSION 
	  	  	  
	  
Artemisinin and its derivatives have been reported extensively to be good 
examples of natural product drug discovery considering their role in the 
treatment of malaria (Cragg & Newman 2005). Moreover, they are also 
promising lead natural products as many studies have reported their role in 
the treatment of various cancers as discussed in section 1.2.2. This project 
took advantage of the potential role of artemisinin as a drug lead by linking 
the most potent artemisinin like-compound dihydroartemisinin (DHA) with an 
iodo-isatin azide intermediate compound to form a hybrid compound in order 
to improve anticancer activity.  
  
In this project the effect of DHA (first generation derivative of artemisinin), 
cisplatin, a drug currently used for chemotherapy, and the novel hybrid 
artemisinin compound EXP57EA were assessed on a panel of cancer cell 
lines. Yde & Issinger et al. 2006 reported that a major drawback of certain 
compounds such as cisplatin is the severe dose effect on various cancers, 
which consequently develop resistance to the treatment (Yde & Issinger 
2006). This was demonstrated in this study where the IC50 values for cisplatin 
in KYSE150, MDA-MB-231 and SiHa cell lines, were 86 µM, 108.1 µM and 
71.1 µM respectively. Moreover, it was also observed that in MDA-MB-231 
and SiHa cell lines DHA was not active (NA), unlike WHCO1 and WHCO5 
cell lines. A previous study in our laboratory reported that the IC50 value of 
DHA in KYSE150 cell line was 27.9 µM (Shunmoogam-Gounden 2014), 
whereas in this study DHA was not able to kill KYSE150 cells. It is possible 
that the KYSE150 cells in the previous study were contaminated with 
mycoplasma, although mycoplasma assays are routinely conducted in our 
laboratory. It is difficult to explain this difference, since the EXP57EA had the 
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same purity profile as previous batches, and the hybrid compound displayed 
the same biological profile as reported previously. It has been reported that 
hybrid compounds often display different or better activity than their parental 
compounds (Teiten et al. 2014). It was shown in this study that the novel 
hybrid compound EXP57EA was more active with IC50 values not exceeding 
30 µM across all cell lines, than DHA and cisplatin.   
Previous studies have reported the anticancer effect of artemisinin 
derivatives and demonstrated their ability to induce apoptosis or autophagy 
in various cancer cell lines (Chen et al. 2014; Du et al. 2013; Hou et al. 
2008). Previously in our laboratory, it was shown that the first generation 
derivative artemisinin compound DHA had a different molecular mechanism 
of action compared to the novel hybrid compound EXP57EA. It was shown 
previously in our laboratory that DHA induced apoptosis based on various 
assays performed on two esophageal cell lines, whereas EXP57EA induced 
autophagy based on tests performed on the same cell lines.   
In this study, the cytotoxic effect of EXP57EA and its parental compound 
DHA was examined on all cell lines tested. The first part of this study was 
focused on determining the concentration of DHA and EXP57EA required to 
kill the cancer cells. Having found the treatment conditions, the effect of 
these two compounds on cell morphology was investigated (figures 2.3 and 
2.4). Cells treated with DHA showed signs of apoptosis such as cell 
shrinkage. Moreover, PARP was cleaved when the same cells were treated 
with DHA. These results are consistent with previous results found in our 
laboratory in WHCO1 cell line (Shunmoogam-Gounden 2014) and also 
reported by Hou et al. where they demonstrated that DHA and another first 
generation artemisinin compound (artesunate) induced apoptosis in HepG2 
liver cancer cells based on cleaved PARP expression (Hou et al. 2008).  
All cells treated with EXP57EA showed no PARP cleavage, consistent with 
previous results found in our laboratory for the WHCO1 cell line 
(Shunmoogam-Gounden, 2014). In this study, the inability of EXP57EA to 
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induce PARP cleavage was observed in a larger panel of cancer cell lines. 
Here, extensive experimental approaches were also used to show that 
EXP57EA activated autophagy. These include appearance of vacuoles in 
cells treated with EXP57EA, analysis of Beclin1 and LC3-II by western blot 
as well as increased autophagic flux. When all cell lines were treated with 
EXP57EA, signs of autophagy such as perinuclear vacuoles were observed. 
A change in the expression level of Beclin1 upon EXP57EA treatment was 
seen in all cell lines and this suggested that autophagy occurred since 
Beclin1 is necessary for the induction of autophagy (figure 2.6). Another 
standard method to show the induction of autophagy is the analysis of LC3-II 
by western blot. When autophagy occurs, LC3 is cleaved by ATG4 to LC3-I 
allowing conjugation of LC3-I to PE, generating the lipidated form LC3-II (17 
kDa), which is mainly involved in the elongation of the autophagosome 
structure. Thus LC3-II is a good marker to measure autophagic activity. In 
this study, we showed that EXP57EA treatment activated LC3-II in all cell 
lines and this was also suggestive of autophagy (figure 2.7). It was previously 
demonstrated in our laboratory that EXP57EA increased Beclin1 and LC3-II 
expression level in WHCO1 and WHCO6 cell lines and this was confirmed in 
this study for the WHCO1 cell line. Given the novelty of EXP57EA, it has 
never been reported that this compound increased the expression level of 
Beclin1 and LC3-II in the other cell lines selected in this study. Various 
studies have reported that certain compounds caused increased levels of 
Beclin1 and LC3-II markers in various cancers, which were suggestive of 
autophagy (Jia et al. 2014; He et al. 2010). However, according to Klionsky 
et al. 2016, these results are insufficient to conclude that EXP57EA activates 
autophagy (Klionsky et al. 2016). To determine if a compound truly activates 
autophagy, one should analyze LC3-II turnover as a marker of autophagic 
flux by western blot. Autophagic flux refers to the rate of the autophagic 
process resulting in the degradation of the autolysosomal content (Loos et al. 
2014). A study conducted by Jeon et al. demonstrated that 2-deoxyglucose 
increased autophagic flux in human prostate cancer cells (PC3 cells) (Jeon 
et al. 2015). Another study showed that Bufalin increased autophagic flux in 
U87MG and LN229 glioma cell lines (Shen et al. 2014a). In this study two 
inhibitors NH4Cl and chloroquine were used and it was found that EXP57EA 
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increased the autophagic flux in both WHCO1 and SiHa cell lines. Other 
approaches to show autophagic flux include the use of Bafilomycin A1, 
pepstatin A and lysosomal proteases such E64d (Klionsky et al. 2016; Zhang 
et al. 2013). The use of NH4Cl and chloroquine to inhibit the autophagy 
process has been reported in various studies (Abdel-Aziz et al. 2014; M. Li et 
al. 2013) and the data obtained in this study showed that EXP57EA activated 
the autophagy pathway, resulting in increased LC3-II turnover. Considering 
that apoptosis is the preferred mode of cell death induced by anti-cancer 
agents, it was interesting to see that EXP57EA induced a different pathway 
in all cell lines tested.    
  
Various drugs that have been used for research in various diseases including 
cancer induce autophagy (Levine et al. 2015). These include, inhibitors of 
mTOR such as Torin 1 in MEF cells and PP242 in leukemia cells (Thoreen et 
al. 2009; Janes et al. 2010; Sarkar 2013). Another example of a dug inducing 
autophagy is the ABT737 4-[4-[[2-(4-chlorophenyl) phenyl]methyl] piperazin-
1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-
nitrophenyl] sulfonylbenzamide) drug. This drug inhibited the Bcl-2 family of 
proteins by acting as BH3 mimetic. The latter disrupted the interaction of Bcl-
2 and Beclin1 to induce autophagy in Hela cells (Maiuri et al. 2007; Thorburn 
et al., 2014). 
  
    
Preliminary evidence in our laboratory showed that EXP57EA activated 
autophagy through the ER stress pathway via the activation of CHOP in 
WHCO1 and WHCO6 cell lines. Various studies have linked the 
PERK/eIF2α/ATF4 unfolded protein response (UPR) signaling pathway to the 
activation of autophagy via phosphorylated eIF2α-triggered activation of LC3-
II in Huntington and Parkinson diseases. A study done by Lugea et al. 2011 
and a review by Szegezdi et al. 2006 reported that once ER stress occurs, 
the first sensor to be activated is PERK. It plays an important in the 
phosphorylation of eukaryotic translation initiation factor 2α (eIF2α), resulting 
in the inhibition of protein translation and the activation of two important 
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autophagy markers such as Autophagy protein 5 (Atg5) and Microtubule-
associated light chain 3 (LC3) through activating transcription factor 4 (ATF4) 
and the C/EBP homologous proteins (CHOP) (Lugea et al. 2011; Szegezdi et 
al. 2006). In accordance with that, we investigated the effect of EXP57EA on 
the PERK/eIF2α pathway and the involvement of ROS production in that 
process. Tempol, a superoxide anion scavenger was used. Tempol is a 
membrane permeable, metal-independent superoxide dismutase mimetic for 
superoxide anions. It has been reported that superoxide can be produced by 
the microsomal monooxygenase (MMO) system of the ER, therefore 
activating the UPR and resulting in autophagy (Chen et al. 2009). Results of 
this study showed that EXP57EA treatment alone (15 µM) stimulated 
phosphorylation of eIF2α. However, in the presence of tempol the level of p-
eIF2α decreased significantly (figure 2.9). These results were consistent with 
a study reported by Jiang et al., 2013 where Selenite stimulated 
phosphorylation of eIF2α in Jurkat cells (Jiang et al. 2013). Moreover, Dong 
et al showed that tempol attenuated the expression level of eIF2α in Bovine 
aortic endothelial cells (BAECs) (Dong et al. 2010). 
  
As mentioned earlier, PERK/eIF2α has been reported to induce autophagy 
through the activation of CHOP. All cell lines selected in this study were 
treated with EXP57EA and the results showed an increase in CHOP mRNA 
expression level except in KYSE150 cell line.  These results are consistent 
with a study done by Shimodaira et al. 2014, where the mRNA expression 
level of CHOP was elevated in HT29 colon cancer cells treated with 
thapsigargin (Shimodaira et al. 2014). We concluded that EXP57EA 
activated the PERK/eIF2α/CHOP pathway. However, further work needs to 
be done to show that EXP57EA activates autophagic cell death through the 
PERK/eIF2α/CHOP pathway. 
Various signaling pathways have been implicated in autophagic cell death. 
Among them is the c-Jun NH2-terminal kinase (JNK) pathway (He & Klionsky 
2009; Yu et al. 2006). Therefore, we investigated the effect of EXP57EA 
treatment on p-c-jun and total c-jun levels in WHCO1 and WHCO5 cell lines. 
Treated cells stimulated phosphorylation of c-jun, however, when a JNK 
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inhibitor SP600125 was added a dose-dependent decrease of p-c-jun and 
elevated levels of total c-jun were seen in both cell lines. It has been reported 
that autophagy was inhibited in IRE1-MEF deficient cells or in cells treated 
with SP600125, a JNK inhibitor, suggesting that IRE1-JNK is necessary for 
autophagy and that JNK played an important role in autophagy (Jia et al. 
2014; Ogata et al. 2006). In this study, these results suggested that 
EXP57EA might also play a role in the JNK activation, which has been 
implicated in autophagic cell death. However, more work needs to be done to 
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CHAPTER 4:  
  




Cancer represents a major burden worldwide and the number of diagnosed 
cancer patients has been reported to double by the year 2030. It is well 
known that diagnosing cancers at an early stage of the disease provides 
patients with the best possible chance of survival. However, for the present 
time, there are some cancers that will be diagnosed at a late stage. The 
mortality rate of this disease could be reduced if improved chemotherapeutic 
agents could be developed. Effective chemotherapy includes anticancer 
agents that kill cancer without damaging normal cells. Natural products have 
proven to be an incredible source of compounds that could be developed into 
chemotherapeutic agents, therefore the aim of this project was to investigate 
a novel derivative of a natural product against cancer cells.  
This project focused on an artemisinin derivative originally obtained from a 
plant used in traditional medicine. The novel hybrid compound was 
synthesized by conjugating the most potent artemisinin compound DHA, with 
an iodo-isatin intermediate and a novel isatin-artemisinin derivative 
EXP57EA was generated. In this study it was shown that the novel derivative 
displayed greater activity than DHA and cisplatin across all cell lines. 
Moreover, SiHa and MDA-MB-231 cell lines, which have been reported to be 
resistant, were more sensitive to the novel hybrid compound than its parental 
compound DHA.   
This study investigated some of the effects of EXP57EA. The role of 
autophagy in cancer is complex since this process has been reported to play 
a role in cell survival and cell death. In this study, our results showed that 
EXP57EA activates autophagy since no evidence of apoptosis was seen. 
Moreover, autophagic flux estimations using ammonium chloride and 
chloroquine showed that the complete autophagy was activated by 
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EXP57EA. Various signaling pathways have been implicated in autophagic 
cell death. In this study, EXP57EA was demonstrated to activate 
PERK/eIF2α/CHOP as well as the JNK pathways, which have been reported 
to induce autophagic cell death.   
Future work in this study will be done to show that EXP57EA activates 
autophagy by measuring the autophagic flux in the other cell lines selected 
for this study. Furthermore, the effect of EXP57EA-induced autophagic cell 
death through the PERK/eIF2α/CHOP and JNK pathway will also be 
investigated by analyzing the expression level of LC3-II by western blot. To 
implicate EXP57EA as a cell death mechanism, it would also be interesting 
to determine the effect of inhibiting CHOP using siRNA in combination with 
the JNK inhibitor SP600125 on LC3-II expression levels.  It would be very 
interesting to also determine the effect of the autophagy rescue agents 
(ammonium chloride, chloroquine, tempol and SP600125) on cell number 
when treated in combination with EXP57EA. 
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CHAPTER 5:  
  
MATERIALS AND METHODS  
	  	  
	  
5.1    Cell culture   
5.1.1 Cell lines   
 
The esophageal cancer lines WHCO1 and WHCO5 were derived from 
biopsies of primary esophageal squamous cell carcinomas and kindly 
provided by Professor Rob Veale (University of Witwatersrand, South Africa) 
(Shunmoogam-Gounden 2014).  The KYSE150 an esophageal squamous 
cell carcinoma cell line was previously established by Shimada and co-
workers (Shimada et al. 1992), was purchased from the German Resource 
Centre for Biological Material (http://www.dsmz.de).  The SiHa cervical 
cancer cell line and MDA-MB-321 breast cancer cell line were purchased 
from the American Type Culture collection (Rockville, MD, USA).   
 
5.1.2 Cell Culture   
 
All cell lines were cultured in Dulbecco’s Modified Eagles Medium (DMEM) 
(Invitrogen, USA) supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin and 10% Fetal Bovine Serum (FBS) (Gibco, Paisley, Scotland). 
Dishes (10 cm) were incubated in a humidified incubator at 37˚C and 5 % 
CO2 until 70 % - 80 % confluency was reached.      
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5.1.3 TrypsinIzation   
   
Once the cells reached 70 % - 80 % confluency, trypsinization was 
performed as follows:  
The DMEM media in dishes was discarded. Thereafter, cells were washed 
with 5 ml Trypsin- EDTA. The EDTA was discarded and 5 ml of fresh 
Trypsin-EDTA was added to the dishes to trypsinize the cells. The cells were 
incubated for 3 min at 37˚C. DMEM media was added to the cells to 
inactivate the action of trypsin and the cell suspension was transferred in a 
12 ml falcon tube and centrifuge at 1000 rpm for 3 min to obtain pellets.  The 
solution containing media and centrifuge was aspirated off and the pellets 
were resuspended with 5 ml complete DMEM. A fresh 100 mm culture dish 
was prepared containing 9 ml of fresh media and 1 ml of the resuspended 
cell was added to the dish.   
  
 5.1.4 Mycoplasma Test    
  
Mycoplasma tests were routinely performed to ensure that the cells were not 
contaminated.  Cells were culture in complete DMEM until 60 % - 80 % 
confluency was reached.  Cells were trypsinized as describe in section 5.1.3, 
however the pelleted cells were resuspended in penicillin and streptomycin 
free media and plated onto a cover slip. After 24 hours incubation, cells were 
washed with 1 x PBS and fixed with methanol for 10 min. Fixed cells were 
further washed with 1 x PBS and stained with DAPI. The cover slip was 
mount with mowiol 4-88 (Calbiochem#475904) and cells were kept in the 
dark for 24 hours, following visualization on the phase contrast microscope 
(Axiovert 200 M microscope (Zeiss)). Images were taken using an Axio 
CamHR camera with Axiovision software, version 4.7 (Zeiss). Stained nuclei 
appeared blue and tiny spots in the cytoplasm indicated mycoplasma 
contamination.   
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5.2    Compounds and Inhibitors     
	  
The two compounds Dyhidroartemisinin (DHA) and EXP57EA were received 
from the Chemistry Departement, UCT (assessed to be 95 % pure) and 
dissolved in tissue culture grade DMSO (Sigma-Aldrich® co). Cisplatin, 
Doxorubicin (DOX), ammonium chloride (NH4Cl) , chloroquine and JNK 
inhibitor (SP600125) were were  purchased from Sigma-Aldrich® co and  
dissolved in tissue culture grade DMSO with the exception of Cisplatin and 
ammonium chloride which were dissolved in 0.9 % saline solution and sterile 
dH20 respectively.  
   
5.3   Proliferation assay       
 
Cells were plated at a density of 3 x 103 cells/well in a 96 well plate (90 µl per 
well) and incubated for 24 hours. Treatment of cells included DHA, EXP57EA 
and Cisplatin at different concentrations. Controls were treated with DMSO. 
Plated cells were incubated for 48 hours at 37˚C in a CO2 incubator. 
Following 48 hours of treatment, 10 µl of MTT reagent (100mg/20ml 1 X 
PBS) was added to each well before adding the solubilizing reagent and 
incubated for 4 hours at 37˚C. Absorbance was then measured at 595nm 
using the plate reader in conjunction with the Gen 5 Data analysis software. 
The dose response curve was then plotted using PRISM software.     
  
 
 5.4    Western blot analysis   
5.4.1 Plating of cells  
 
All cell lines were cultured and trypisinized as described in section 5.1.3. The 
cells were counted using a haemocytometer. The cells were plated in 6 cm 
dishes at a cell density of 0.75 x 105 cells/dish. The dishes were placed in a 
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CO2 incubator overnight. Treatment was done using the same drugs 
mentioned in section 5.3.    
  
 5.4.2 Protein extraction   
	  
Following treatment of cells on dishes with the desired compound, media 
was transferred to a 12 ml tube and kept on ice. Cells were washed with 1 X 
PBS and the PBS wash was added to the originally collected media. Cells 
were centrifuged at 10000 rpm for 5 min at room temperature. Pellets were 
resuspended with 60 µl of a cocktail containing radioimmunoprecipitation 
assay buffer (RIPA) (150 mM NaCl, Triton X-100, 0.5% Sodium 
deoxycholate, 0.1% SDS and 50 mM Tris), 1 X protease inhibitors (Sigma, 
USA) 1 mM Sodium orthovanadate (Na3V04) and 1 mM Sodium Fluoride 
(NaF) were added. The cocktail was added to the dishes and cells were 
scraped off using a cell scraper. Cell lysates were mixed with the resupended 
pellets and sonicated for 5 sec on ice. Cells were then centrifuged at 4˚C for 
5min at 10000 rpm. The supernatant was transferred to a new 
microcentrifuge tube and proteins were quantified using the BCA 
(Bicinchoninic Acid) assay kit (Pierce Thermo Scientific, USA). Absorbance 
was measured at 595nm and proteins concentrations were determined using 
a set of BSA standards.      
 
5.4.3 SDS-PAGE  
	  
Proteins samples were prepared by the addition of 6 X loading dye. The final 
volume was made up with RIPA buffer. Samples were heated at 90˚C for 5 
min to denature proteins. Proteins (20 µg or 40 µg) were loaded onto a 10% 
polyacrylamide gel and electrophoresed at 160 V for approximately 1 hour in 
1 X running buffer. Proteins within the gel were transferred onto a 





5.4.4 Membrane probing  
After transfer, the membrane was blocked in 5% milk powder (Elite fat free 
instant milk powder) with TBST (TBS Tween) for 1 hour 30 min at room 
temperature with gentle shaking. After blocking, the membrane was briefly 
washed with TBST.  The membrane was probed with primary antibodies (see 
table 1) and the membrane left overnight at 4˚C with agitation.  Following 
incubation, the membrane was washed three times with TBST for 5 min each 
and incubated with secondary antibodies for 1 hour at room temperature with 
gentle shaking. Finally the membrane was washed once again three times 
with TBST.     
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Table 5.1: Antibodies concentrations and incubations conditions 
5.4.5 Immunodetection 
Proteins bands were detected using LumiGLO, a lumino-based 
chemiluminescent substrate (KPL, USA) or Clarity™ Western ECL substrate. 
The membrane was incubated with equal volume of substrate A and B for 1 
min and 5 min for LumiGLO, a lumino-based chemiluminescent substrate 
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was then exposed to X-ray film for the desired time. The x-ray film was 
developed until the bands of interest appeared.  
5.4.6 Membrane striping 
Membrane could be reprobed with different antibodies following stripping. 
Membranes were stripped with 10 % acetic acid (see appendix) for 10 min at 
room temperature with gentle shaking. Following stripping, membranes were 
washed 3 times with TBST for 5 min each at room temperature with gentle 
shaking. The membranes were then blocked and probed as above (section 
5.4.4) according to the antibody condition.  
5.5    RNA extraction, quantification and preparation for real-time PCR  
5.5.1 RNA extraction from cultured cells 
In order to extract RNA, 3 ml of complete media containing 8 x 104  cells 
were plated in 60 mm dishes and incubated for 24 hours, after which cells 
were treated with 15 µM of EXP57EA for 24 hours. RNA was harvested from 
each dish with QIAzol (300 µl per 3 ml) (Qiagen, Germany). Briefly, cells 
were washed twice with ice cold 1 x PBS, after which QIAzol was added to 
cells and incubated for 5 min at room temperature. RNA was then scraped 
off using a cell scraper and transferred to a chilled eppendorf tube. 
Subsequently, 60 µl of Chloroform per 1 ml of QIAzol was added to each 
sample, mixed vigorously for 15 s followed by 2-3 min incubation at room 
temperature. The samples were centrifuged at 12000 x g at 4˚C for 15 min in 
order to separate the two phases. The upper aqueous phase was transferred 
to a clean tube and RNA was precipitated using 150 µl isopropanol (1/2 
volume of QIAzol) and the tubes were inverted gently. This was followed by 
10 min incubation at room temperature and the samples were centrifuged at 
12000 x g at 4˚C for 10 min. The supernatant was discarded and RNA pellets 
were washed with 70 % ethanol followed by centrifugation at 12000 x g (4˚C) 
for 5 min. The supernatant was discarded and the RNA pellets were air-dried 
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for 15-20 min and the pellet were resuspended with 30 µl 
diethylpyrocarbonate (DEPC) - treated water.  DEPC-treated water was 
prepared by thoroughly dissolving 1 ml of DEPC in 1 L of distilled water (0.1 
% DEPC-treated water). After an overnight incubation, the DEPC-treated 
water was autoclaved.  
5.5.2 Quantification 
RNA was quantified using the NanodropTM 2000c spectrophotometer 
(Thermo Scientific, USA) and 2 µg was mixed with RNA loading dye 
(containing 0.5 µg/ml ethidium bromide) and electrophoresed on a 1.5 % 
MOPS/formaldehyde agarose gel to see if the extracted RNA were 
contaminated.   
5.5.3 cDNA synthesis 
cDNA was prepared by mixing 3 µg of the total RNA with a desired volume of 
DEPC-dH20 and 0.5 µg (1µl) of oligo-(dT)20 primer (Promega, USA) was 
added to a final volume of 9 µl. The two samples were placed at 70˚C for 5 
min following incubation on ice for 5 min. Subsequently, 1 µl ImPromII 
Reverse Transcriptase II, 40 units of RNAsin RNase inhibitor, 1.2 mM MgCl2, 
5 x reaction buffer and 3.3 mM dNTPs  (all reagents were purchased from 
Promega, USA) were added to each sample to a final volume of 20 µl. The 
sample were incubated at RT for 5 min, 42˚C for 1 hour, 70˚C for 15 min and 
the resultant cDNA was placed on ice until use for quantitative real-time PCR 
or store at -80° C.     
5.5.4 Quantitative real-time PCR 
Quantitative real time reverse transcription polymerase chain reaction was 
performed using the StepOne Real-time PCR system (Applied Biosystems, 
USA), and the comparative threshold cycle (CT) method was used to analyse 
values generated. Real-time PCR was performed using the KAPA SYBR 
Qpcr master mix. 20 µM of the housekeeping gene’s primers GusB or 10 µM 
of the gene of interest’s primers CHOP were added to 2 µl cDNA and 2 µl 
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DEPC-treated water was use as Positive control. Gus B forward primer was 
5- CTC-ATT-TGG-AAT-TTT-GCC-GAT -3’. Reverse: 5’- CCG-AGT-GAA-
GAT-CCC-CTT TTT –‘3. CHOP forward primer was 5’- ACC- TCC-THGG An
AAA-TGA- AGA GGGA- AG -
,3 and the reverse primer was 5 % TCT-CCT- TCA0TGC-GCT-GCT-TT-
3mM. The PCR cycling conditions were 95˚C for 3 min followed by 40 cycles
of denaturation at 95˚C for 1 s, annealing at 60˚C (GusB and CHOP primers)
for 20 s and finally 95˚C for 15 s. CT values were calculated using StepOne
Version 2.0 software (Applied Biosystems) and the Delta Delta CT method
was used to calculate the expression of target mRNA relative to that of the
housekeeping gene, either β-glucuronidase (GusB) or Glyceraldehyde 3-
phosphate dehydrogenase (GADPH). PCR products were electrophoresed
on a 2 % gel to ensure that single specific PCR product was amplified and
that there was no contamination or primer-dimer formation. Samples were
mixed with 6 x loading dye and electrophoresed at 80 V for 1 hour. A DNA
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APPENDIX A: SOLUTIONS 
 
 
 Protein solutions   
 
1M Tris pH 6.8   
                               
60.5 g Tris  
300 ml dH2O   
pH with concentrated HCl to pH 6.8   
Volume made up to 500 ml with dH2O     
 
1 M Tris pH 8.8        
 
60.5 g Tris  
300 ml dH2O   
pH with concentrated HCl to pH 8.8   
Volume made up to 500 ml with dH2O   
  
 RIPA Buffer    
                             
150 mM NaCl                
1% Triton x-100   
0.5% Sodium Deoxycholate   
0.1% SDS   
50 mM Tris, pH 8.0     
  
10 X PBS    
 
40 g NaCl  
1 g KCl  
1 g KH2PO4   
3.82 g Na2HPO4.2H2O  
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Western Blot solutions  
 
10% stacking gel  
                            
2.75 ml dH2O   
3.75 ml 1M Tris PH 8.8   
100 µl 10% SDS     
3.35 ml 30% acrylamide   
200 µl 10% APS  
20 µl TEMED     
  
Resolving gel    
                                 
3.65 ml dH20   
625 µl 1M Tris, pH 6.8   
50 µl 10% SDS   
650 µl 30% acrylamide    
60 µl 10% APS   
6 µl TEMED     
 
15% stacking gel  
                            
2.3 ml dH20    
1.67 ml  1M Tris PH 8.8   
100 µl 10% SDS     
5 ml 30% acrylamide      
100 µl 10% APS  
10 µl TEMED        
 
Resolving gel   
                                  
3 ml dH20    
2.5 ml 1M Tris, pH 6.8   
50 µl 10% SDS  
670 µl 30% acrylamide       
50 µl 10% APS   
5 µl TEMED                         
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10 X Running Buffer   
                     
20 g Glycine  
31.6 g Tris  
50 ml 10% SDS   
Up to 500 ml with dH2O  
   
1 X Running Buffer   
  
100 ml 10 X running buffer  
900 ml dH2O  
  
10 X Transfer Buffer    
                         
72 g Glycine   
19 g Tris   
Up to 500 ml with dH2O   
  
1 X Transfer Buffer  
                         
200 ml Isopropanol    
100 ml 10 X Transfer Buffer   
700 ml dH2O     
  
6 X loading dye    
 
0.8 ml Glycerol   
0.1 ml Bromophenol Blue   
0.5 ml Tris pH 6.8  
0.6 ml 20 % SDS   
10 µl 100% β-mercaptoethanol  
  
  
10 X TBS  
                                              
24.23 ml Trizma (HCl) or Tris  
80.06 g NaCl   
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Mix in 800 ml dH2O    
pH with concentrated HCl to pH 7.6   
Volume made up to 1000 ml dH2O   
   
1 X TBST    
                                           
100 ml 10 X TBS   
900 ml dH2O   
1 ml Tween-20   
 
5 % milk powder     
                         
5 g milk   
100 ml TBST 
  
MTT and drugs treatment assays 
  
MTT (100mg/20ml)     
                      
100 mg MTT    
20 ml 1X PBS  
Vortex and incubate for 15 min at 37˚C    
Filter through a 0.2 µm filter   
Wrap in foil and store in the dark at 4˚C for up to 1 month  
  
Solubilisation reagent      
               
25 g SLS   
Up to 250 ml with dH2O       
76.6 µl concentrated HCl          
 
RNA isolation and Electrophoresis  
  
DEPC-treatment    
                           
0.1 % DEPC in distilled dH2O   
Stir for one hour at room temperature  
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RNA gel   
                                            
0.75 g agarose   
42 ml dH2O   
Heat and allow to cool   
Add 5 ml 10 X MOPS   
2.7 ml Formahaldehyde   
 
10 X MOPS  
                                          
41.86 g MOPS   
16.6 ml 3 M NaAcetate   
20 ml 0.5 M EDTA (pH 7.0)   
Adjust to 1L (DEPC-H2O)   
Cover in foil and store a 4°C 
Dilute to 1X MOPS as needed  
  
2 X RNA loading Dye  
                           
0.72 ml Formamide   
0.16 ml 10 X MOPS   
0.26 ml Formaldehyde  
0.04 ml dH2O  
0.1 ml glycerol   
0.2 ml bromophenol blue (0.25 % Depc-dH2O)  
50 µg/ml ethiduium bromide   
Store at - 20˚ C  
  
DNA electrophoresis     
  
10 X TBE  
                                              
108 g TRIS   
55 g Boric acid   
7.4 g EDTA  
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2 % Agarose gel    
                                  
2 g Agarose      
10 ml 1 X TBE  
90 ml dH2O   
2 µl ethidium bromide  
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APPENDIX B 
 
              
  
 
   
  
  







	  	                                                                 
 
   
 
  
   
  
 




   
 
               
      
            Figure 2: O’ Genruler 1kb DNA for use a ladder 
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